{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9c44ff08",
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install sovai[full]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Clinical Trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Downloading and saving new file.\n",
      "Downloading and saving new file.\n"
     ]
    }
   ],
   "source": [
    "import sovai as sov\n",
    "\n",
    "sov.token_auth(token=\"visit https://sov.ai/profile for your token\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Prediction Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting data request for endpoint: clinical_trials\n",
      "Enabling full_history due to date range specification\n",
      "Prepared endpoint: /clinical_trials\n",
      "Full URL: https://data.sov.ai/clinical_trials with params: {'tickers': 'PFE,GE', 'from_date': '2017-11-20T00:00:00', 'to_date': '2020-11-20T00:00:00', 'parquet': 'True', 'full_history': 'True'}\n",
      "Cache key: a160d52c5266fc670f1d469b767ca4de39a5d770fad83e49a96664708cd090a7\n",
      "Grabbing S3 Partitioned High client side\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Loading data: 100%|██████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████████| 2/2 [00:01<00:00,  1.34it/s]\n"
     ]
    }
   ],
   "source": [
    "df_apps = sov.data(\"clinical_trials\", tickers=[\"PFE\",\"GE\"], start_date=\"2017-11-20\", end_date=\"2020-11-20\", verbose=True, purge_cache=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>date</th>\n",
       "      <th>source</th>\n",
       "      <th>subsidiary</th>\n",
       "      <th>sponsor</th>\n",
       "      <th>trial_id</th>\n",
       "      <th>official_title</th>\n",
       "      <th>sponsor_study_id</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>lead_sponsor_name</th>\n",
       "      <th>sponsor_type</th>\n",
       "      <th>lead_sponsor_type</th>\n",
       "      <th>phase_category</th>\n",
       "      <th>study_type</th>\n",
       "      <th>enrollment_count</th>\n",
       "      <th>number_of_locations</th>\n",
       "      <th>healthy_volunteers</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>study_size_category</th>\n",
       "      <th>condition_keywords</th>\n",
       "      <th>primary_condition</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>primary_intervention</th>\n",
       "      <th>intervention_name</th>\n",
       "      <th>intervention_arm_group_labels</th>\n",
       "      <th>intervention_description</th>\n",
       "      <th>has_data_monitoring_committee</th>\n",
       "      <th>responsible_party_investigator_affiliation</th>\n",
       "      <th>responsible_party_investigator_title</th>\n",
       "      <th>responsible_party_investigator_name</th>\n",
       "      <th>first_posted_date</th>\n",
       "      <th>last_update_posted_date</th>\n",
       "      <th>start_date</th>\n",
       "      <th>study_completion_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>study_locations_city</th>\n",
       "      <th>study_locations_country</th>\n",
       "      <th>study_locations_geopoint</th>\n",
       "      <th>study_locations_facility</th>\n",
       "      <th>study_locations_zip</th>\n",
       "      <th>study_locations_state</th>\n",
       "      <th>standard_age_groups</th>\n",
       "      <th>sex</th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>maximum_age</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>status_category</th>\n",
       "      <th>status_verified_date</th>\n",
       "      <th>primary_outcomes_measures</th>\n",
       "      <th>primary_outcomes_timeframes</th>\n",
       "      <th>primary_outcomes_descriptions</th>\n",
       "      <th>secondary_outcomes_measures</th>\n",
       "      <th>secondary_outcomes_timeframes</th>\n",
       "      <th>secondary_outcomes_descriptions</th>\n",
       "      <th>has_results</th>\n",
       "      <th>conditions</th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>masking</th>\n",
       "      <th>allocation</th>\n",
       "      <th>intervention_model</th>\n",
       "      <th>primary_purpose</th>\n",
       "      <th>has_expanded_access</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>trial_duration</th>\n",
       "      <th>references_type</th>\n",
       "      <th>references_citation</th>\n",
       "      <th>references_pmid</th>\n",
       "      <th>collaborators_name</th>\n",
       "      <th>collaborators_class</th>\n",
       "      <th>ipd_sharing</th>\n",
       "      <th>success_prediction</th>\n",
       "      <th>economic_effect</th>\n",
       "      <th>duration_prediction</th>\n",
       "      <th>success_composite</th>\n",
       "      <th>class</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>GE</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>listed</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>NCT03354273</td>\n",
       "      <td>A Phase 3, Open-Label, Multicentre Study Of Fl...</td>\n",
       "      <td>GE-265-303</td>\n",
       "      <td>An International Study To Evaluate Diagnostic ...</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>Ge Healthcare</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>730</td>\n",
       "      <td>53</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Large</td>\n",
       "      <td>Positron emission tomography myocardial perfus...</td>\n",
       "      <td>Coronary Artery Disease (Cad)</td>\n",
       "      <td>DRUG; DRUG; DRUG</td>\n",
       "      <td>PET MPI</td>\n",
       "      <td>PET MPI; SPECT MPI; Pharmacological stress agents</td>\n",
       "      <td>1; 1; 1</td>\n",
       "      <td>Flurpiridaz (18F) Injection. All Participants ...</td>\n",
       "      <td>True</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-11-27</td>\n",
       "      <td>2023-07-12</td>\n",
       "      <td>2018-06-05</td>\n",
       "      <td>2022-05-05</td>\n",
       "      <td>2022-05-05</td>\n",
       "      <td>Birmingham; Los Angeles; Los Angeles; Los Ange...</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 33.52066, lon: -86.80249; lat: 34.05223, ...</td>\n",
       "      <td>Vascular Biology and Hypertension Program, Uni...</td>\n",
       "      <td>35294; 90024; 90033; 90073; 92161; 94107; 9040...</td>\n",
       "      <td>Alabama; California; California; California; C...</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>Sensitivity and Specificity of Flurpiridaz (18...</td>\n",
       "      <td>Up to 60 days</td>\n",
       "      <td>Sensitivity was defined as true positives (TP)...</td>\n",
       "      <td>Sensitivity and Specificity of Flurpiridaz (18...</td>\n",
       "      <td>Up to 60 days; Up to 60 days; Up to 60 days; U...</td>\n",
       "      <td>Sensitivity:TP/(TP+FN). TP:participants with a...</td>\n",
       "      <td>True</td>\n",
       "      <td>Coronary Artery Disease (Cad)</td>\n",
       "      <td>This Is A Phase 3, Prospective, Open-Label, In...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>1430</td>\n",
       "      <td>1430.000</td>\n",
       "      <td>DERIVED</td>\n",
       "      <td>Bourque JM, Hanson CA, Agostini D, Bateman TM,...</td>\n",
       "      <td>33521873</td>\n",
       "      <td>Pharmaceutical Product Development, LLC</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>None</td>\n",
       "      <td>0.970</td>\n",
       "      <td>0.620</td>\n",
       "      <td>1430.000</td>\n",
       "      <td>0.828</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>GE</td>\n",
       "      <td>2017-11-28</td>\n",
       "      <td>listed</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>NCT03757598</td>\n",
       "      <td>Epartogram Effectiveness Study: A Mixed Method...</td>\n",
       "      <td>ePartogram Kenya</td>\n",
       "      <td>Epartogram Effectiveness Study In Kenya</td>\n",
       "      <td>Jhpiego</td>\n",
       "      <td>Jhpiego</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>113</td>\n",
       "      <td>12</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Medium</td>\n",
       "      <td>partograph, labor, birth, complications, newbo...</td>\n",
       "      <td>Obstetric Complication</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>ePartogram use</td>\n",
       "      <td>ePartogram use</td>\n",
       "      <td>ePartogram</td>\n",
       "      <td>Electronic Partograph Based On Who Standard Pa...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-11-29</td>\n",
       "      <td>2019-12-11</td>\n",
       "      <td>2016-08-01</td>\n",
       "      <td>2017-05-30</td>\n",
       "      <td>2017-05-30</td>\n",
       "      <td>Kisumu; Kisumu; Kisumu; Kisumu; Kisumu; Kisumu...</td>\n",
       "      <td>Kenya; Kenya; Kenya; Kenya; Kenya; Kenya; Keny...</td>\n",
       "      <td>lat: -0.10221, lon: 34.76171; lat: -0.10221, l...</td>\n",
       "      <td>Ahero Hospital; Kisumu Hospital; Kombewa Healt...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CHILD; ADULT; OLDER_ADULT</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2019-12-01</td>\n",
       "      <td>Percent of partographs showing fetal/newborn w...</td>\n",
       "      <td>All partographs within the 6 month interventio...</td>\n",
       "      <td>Percent of partographs with a suboptimal fetal...</td>\n",
       "      <td>Percent of partographs with a suboptimal mater...</td>\n",
       "      <td>All partographs within the 6 month interventio...</td>\n",
       "      <td>Percent of partographs with a suboptimal mater...</td>\n",
       "      <td>False</td>\n",
       "      <td>Obstetric Complication; Obstetric Labor Compli...</td>\n",
       "      <td>Quasi-Experimental Study To Evaluate Whether C...</td>\n",
       "      <td>The Epartogram Is An Electronic Version Of The...</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>False</td>\n",
       "      <td>302</td>\n",
       "      <td>302.000</td>\n",
       "      <td>BACKGROUND; BACKGROUND</td>\n",
       "      <td>Managing complications in pregnancy and childb...</td>\n",
       "      <td>29743032</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>UNDECIDED</td>\n",
       "      <td>0.940</td>\n",
       "      <td>0.570</td>\n",
       "      <td>302.000</td>\n",
       "      <td>0.743</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>GE</td>\n",
       "      <td>2017-12-01</td>\n",
       "      <td>listed</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>NCT03366662</td>\n",
       "      <td>The Effect Of Frontal Electromyogram (F-Emg) A...</td>\n",
       "      <td>R17108</td>\n",
       "      <td>The Effect Of Frontal Electromyogram (F-Emg) A...</td>\n",
       "      <td>Tampere University Hospital</td>\n",
       "      <td>Tampere University Hospital</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>nan</td>\n",
       "      <td>Electromyography</td>\n",
       "      <td>Anesthesia, General</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Monitoring of frontal electrical muscle activity</td>\n",
       "      <td>Monitoring of frontal electrical muscle activity</td>\n",
       "      <td>None</td>\n",
       "      <td>Continuous Monitoring Of Frontal Electrical Mu...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2017-12-08</td>\n",
       "      <td>2020-03-12</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Tampere</td>\n",
       "      <td>Finland</td>\n",
       "      <td>lat: 61.49911, lon: 23.78712</td>\n",
       "      <td>Tampere University Hospital</td>\n",
       "      <td>33521</td>\n",
       "      <td>None</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>WITHDRAWN</td>\n",
       "      <td>stopped</td>\n",
       "      <td>2020-03-01</td>\n",
       "      <td>Burst suppression electroencephalogram data wi...</td>\n",
       "      <td>One day</td>\n",
       "      <td>Visible EMG</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Anesthesia, General</td>\n",
       "      <td>This Study Evaluates The Effect Of Frontal Emg...</td>\n",
       "      <td>This Is An Academic Observational Study, Where...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.100</td>\n",
       "      <td>0.050</td>\n",
       "      <td>832.000</td>\n",
       "      <td>0.061</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>GE</td>\n",
       "      <td>2018-01-11</td>\n",
       "      <td>listed</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>NCT03409146</td>\n",
       "      <td>Accuracy And Reliability Of A New Intrapartum ...</td>\n",
       "      <td>1404298207</td>\n",
       "      <td>Accuracy And Reliability Of Novii: Fetal Heart...</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>Ge Healthcare</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>80</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Term Labour</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Monica Novii Wireless Patch System</td>\n",
       "      <td>Monica Novii Wireless Patch System</td>\n",
       "      <td>Term Patients</td>\n",
       "      <td>The Monica Novii Wireless Patch System Is A Tr...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-01-24</td>\n",
       "      <td>2021-02-09</td>\n",
       "      <td>2014-05-28</td>\n",
       "      <td>2017-02-13</td>\n",
       "      <td>2017-02-13</td>\n",
       "      <td>Tucson</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 32.22174, lon: -110.92648</td>\n",
       "      <td>University of Arizona Medical Center</td>\n",
       "      <td>85724</td>\n",
       "      <td>Arizona</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2021-02-01</td>\n",
       "      <td>Fetal Heart Rate (FHR) Positive Percentage Agr...</td>\n",
       "      <td>through study completion, an average of 1 year</td>\n",
       "      <td>PPA(%)=(a/(a+C))x100, where \"a\" represents the...</td>\n",
       "      <td>Mean Percentage FHR Equivalence; Uterine Activ...</td>\n",
       "      <td>through study completion, an average of 1 year...</td>\n",
       "      <td>The 2 second output FHR data when both the pre...</td>\n",
       "      <td>False</td>\n",
       "      <td>Term Labour</td>\n",
       "      <td>Accuracy And Reliability Of The Novii Device (...</td>\n",
       "      <td>The Study Is Being Done To Test The Performanc...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>992</td>\n",
       "      <td>992.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.320</td>\n",
       "      <td>0.050</td>\n",
       "      <td>992.000</td>\n",
       "      <td>0.188</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>GE</td>\n",
       "      <td>2018-01-12</td>\n",
       "      <td>listed</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>NCT03417713</td>\n",
       "      <td>Clinical Evaluation Of The Oec Elite Md For Va...</td>\n",
       "      <td>104-2017-GES-0005</td>\n",
       "      <td>Clinical Evaluation Of The Oec Elite Md For Va...</td>\n",
       "      <td>GE Healthcare</td>\n",
       "      <td>Ge Healthcare</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>33</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Interventional Vascular Conditions</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Fluoroscopic imaging with the OEC Elite Device</td>\n",
       "      <td>Fluoroscopic imaging with the OEC Elite Device</td>\n",
       "      <td>All Subjects</td>\n",
       "      <td>Vascular, Gastrointestinal (Gi), Urology Or Pa...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-01-31</td>\n",
       "      <td>2018-11-29</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Hamilton</td>\n",
       "      <td>Canada</td>\n",
       "      <td>lat: 43.25011, lon: -79.84963</td>\n",
       "      <td>Hamilton General Hospital</td>\n",
       "      <td>L8L 2X2</td>\n",
       "      <td>Ontario</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>85</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2018-10-01</td>\n",
       "      <td>Image Guidance Adequacy Collected Via Survey Q...</td>\n",
       "      <td>Approximately 2 months (duration of subject en...</td>\n",
       "      <td>Number of participants whose procedures were c...</td>\n",
       "      <td>Number of Investigator Procedure Surveys Asses...</td>\n",
       "      <td>Approximately 2 months (duration of subject en...</td>\n",
       "      <td>To collect image data acquired during clinical...</td>\n",
       "      <td>True</td>\n",
       "      <td>Interventional Vascular Conditions</td>\n",
       "      <td>The Purpose Of This Study Is To Collect Feedba...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>0.830</td>\n",
       "      <td>0.450</td>\n",
       "      <td>321.000</td>\n",
       "      <td>0.636</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>709</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT04672460</td>\n",
       "      <td>A Phase 1, Open Label, Crossover Study To Esta...</td>\n",
       "      <td>C3441037</td>\n",
       "      <td>A Bioequivalence Study Between The Proposed An...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>73</td>\n",
       "      <td>31</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>PARP inhibitor; Talazoparib; Talzenna; BRCA mu...</td>\n",
       "      <td>Advanced Solid Tumors</td>\n",
       "      <td>DRUG; DRUG; DRUG</td>\n",
       "      <td>TALZENNA capsule</td>\n",
       "      <td>TALZENNA capsule; Talazoparib soft gel capsule...</td>\n",
       "      <td>Sequence 1; Sequence 2; Sequence 1; Sequence 2...</td>\n",
       "      <td>Current Commercial Talazoparib Formulation 1 M...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-12-17</td>\n",
       "      <td>2024-09-25</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Encinitas; Los Angeles; Los Angeles; San Marco...</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 33.03699, lon: -117.29198; lat: 34.05223,...</td>\n",
       "      <td>California Cancer Associates for Research and ...</td>\n",
       "      <td>92024; 90048; 90048; 92069; 06510; 06510; 0651...</td>\n",
       "      <td>California; California; California; California...</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>70</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-06-01</td>\n",
       "      <td>Area Under the Plasma Concentration-Time Profi...</td>\n",
       "      <td>Serial blood sample (4 mL) each was collected ...</td>\n",
       "      <td>AUC24 was defined as area under the plasma con...</td>\n",
       "      <td>Apparent Clearance After Oral Dose (CL/F) of T...</td>\n",
       "      <td>Serial blood sample (4 mL) each was collected ...</td>\n",
       "      <td>Apparent Clearance After Oral Dose (CL/F) was ...</td>\n",
       "      <td>True</td>\n",
       "      <td>Advanced Solid Tumors; Solid Tumors; Ovarian C...</td>\n",
       "      <td>This Will Be A Phase 1, Open Label, 2-Sequence...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>CROSSOVER</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.810</td>\n",
       "      <td>1412.000</td>\n",
       "      <td>0.838</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>710</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2020-11-13</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT04635631</td>\n",
       "      <td>An Open-Label, Single-Arm, Phase 1 Study Of Ph...</td>\n",
       "      <td>C3441049</td>\n",
       "      <td>Study Of Talazoparib Monotherapy In Chinese Pa...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>15</td>\n",
       "      <td>2</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Neoplasms</td>\n",
       "      <td>DRUG</td>\n",
       "      <td>talazoparib</td>\n",
       "      <td>talazoparib</td>\n",
       "      <td>talazoparib</td>\n",
       "      <td>Talazoparib Will Be Administered Orally On A C...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-19</td>\n",
       "      <td>2023-10-10</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Changchun; Beijing</td>\n",
       "      <td>China; China</td>\n",
       "      <td>lat: 43.88, lon: 125.32278; lat: 39.9075, lon:...</td>\n",
       "      <td>Jilin Cancer Hospital; Cancer Hospital, Chines...</td>\n",
       "      <td>130000; 100021</td>\n",
       "      <td>Jilin</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2022-12-01</td>\n",
       "      <td>Maximum Observed Concentration (Cmax) of Talaz...</td>\n",
       "      <td>Pre-dose and 0.5 hours, 1 hour, 2 hours, 4 hou...</td>\n",
       "      <td>Maximum plasma concentration of talazoparib af...</td>\n",
       "      <td>Number of Participants With Treatment-Emergent...</td>\n",
       "      <td>Baseline (the latest non-missing value prior t...</td>\n",
       "      <td>An adverse event (AE) was any untoward medical...</td>\n",
       "      <td>True</td>\n",
       "      <td>Neoplasms</td>\n",
       "      <td>A Phase1 Study To Evaluate The Pk (Single Dose...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.940</td>\n",
       "      <td>0.810</td>\n",
       "      <td>1061.000</td>\n",
       "      <td>0.836</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>711</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2020-11-18</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT04642079</td>\n",
       "      <td>A Phase 3, Single-Arm Trial To Evaluate The Sa...</td>\n",
       "      <td>B7471014</td>\n",
       "      <td>Safety And Immunogenicity Study Of 20Vpnc In H...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>839</td>\n",
       "      <td>43</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Large</td>\n",
       "      <td>nan</td>\n",
       "      <td>Pneumococcal Disease</td>\n",
       "      <td>BIOLOGICAL</td>\n",
       "      <td>20vPnC</td>\n",
       "      <td>20vPnC</td>\n",
       "      <td>Cohort 1: =&gt;15 through 23 months of age; Cohor...</td>\n",
       "      <td>20-Valent Pneumococcal Conjugate Vaccine</td>\n",
       "      <td>True</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-24</td>\n",
       "      <td>2024-01-22</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Fayetteville; Jonesboro; Jonesboro; San Diego;...</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 36.06258, lon: -94.15743; lat: 35.8423, l...</td>\n",
       "      <td>Northwest Arkansas Pediatrics; The Children's ...</td>\n",
       "      <td>72703; 72401; 72401; 92123-1881; 33126; 33184;...</td>\n",
       "      <td>Arkansas; Arkansas; Arkansas; California; Flor...</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>ALL</td>\n",
       "      <td>1</td>\n",
       "      <td>17</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-01-01</td>\n",
       "      <td>Percentage of Participants Reporting Prompted ...</td>\n",
       "      <td>Within 7 days after vaccination on Day 1; With...</td>\n",
       "      <td>Local reactions included redness, swelling and...</td>\n",
       "      <td>Percentage of Participants With Predefined Lev...</td>\n",
       "      <td>At 1 Month after vaccination on Day 1; Before ...</td>\n",
       "      <td>Pneumococcal serotype-specific IgG concentrati...</td>\n",
       "      <td>True</td>\n",
       "      <td>Pneumococcal Disease</td>\n",
       "      <td>This Study Is Designed To Evaluate The Safety ...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>YES</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.880</td>\n",
       "      <td>889.000</td>\n",
       "      <td>0.913</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>712</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2020-11-19</td>\n",
       "      <td>listed</td>\n",
       "      <td>Arena Pharmaceuticals</td>\n",
       "      <td>Arena Pharmaceuticals</td>\n",
       "      <td>NCT04655599</td>\n",
       "      <td>Effect Of Olorinab On Gastrointestinal Transit...</td>\n",
       "      <td>APD371-106</td>\n",
       "      <td>Effect Of Olorinab On Gastrointestinal Transit...</td>\n",
       "      <td>Arena Pharmaceuticals</td>\n",
       "      <td>Arena Pharmaceuticals</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>Olorinab; APD371; Irritable bowel syndrome; IB...</td>\n",
       "      <td>Irritable Bowel Syndrome</td>\n",
       "      <td>DRUG; DRUG</td>\n",
       "      <td>Olorinab</td>\n",
       "      <td>Olorinab; Placebo</td>\n",
       "      <td>Olorinab, Then Placebo; Placebo, Then Olorinab...</td>\n",
       "      <td>Olorinab Tablet By Mouth, 3 Times A Day For 4 ...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-12-07</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>2021-01-29</td>\n",
       "      <td>2021-04-13</td>\n",
       "      <td>2021-04-13</td>\n",
       "      <td>Rochester</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 44.02163, lon: -92.4699</td>\n",
       "      <td>Mayo Clinic</td>\n",
       "      <td>55905</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>70</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>stopped</td>\n",
       "      <td>2021-05-01</td>\n",
       "      <td>Colonic transit geometric center after consump...</td>\n",
       "      <td>up to 24 hours 30 minutes after consumption of...</td>\n",
       "      <td>None</td>\n",
       "      <td>Colonic transit geometric center after consump...</td>\n",
       "      <td>up to 48 hours 30 minutes after consumption of...</td>\n",
       "      <td>Safety will be assessed by monitoring adverse ...</td>\n",
       "      <td>False</td>\n",
       "      <td>Irritable Bowel Syndrome</td>\n",
       "      <td>A Phase 1B Study To Determine The Effect Of Or...</td>\n",
       "      <td>This Is A Single-Center, Randomized, Crossover...</td>\n",
       "      <td>DOUBLE</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>CROSSOVER</td>\n",
       "      <td>BASIC_SCIENCE</td>\n",
       "      <td>False</td>\n",
       "      <td>74</td>\n",
       "      <td>74.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.160</td>\n",
       "      <td>0.510</td>\n",
       "      <td>74.000</td>\n",
       "      <td>0.288</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>713</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2020-11-20</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT04645966</td>\n",
       "      <td>A Phase 2B Trial To Assess The Safety, Tolerab...</td>\n",
       "      <td>C3511002</td>\n",
       "      <td>A Clinical Trial To Assess The Safety, Tolerab...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_2</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>326</td>\n",
       "      <td>21</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Medium</td>\n",
       "      <td>Meningococcal Vaccine; Invasive Meningococcal ...</td>\n",
       "      <td>Meningococcal Vaccine</td>\n",
       "      <td>BIOLOGICAL; BIOLOGICAL; BIOLOGICAL; BIOLOGICAL...</td>\n",
       "      <td>MenABCWY</td>\n",
       "      <td>MenABCWY; Bivalent rLP2086 (60-µg Dose); Bival...</td>\n",
       "      <td>Blinded: MenABCWY and placebo with SLP or TLP ...</td>\n",
       "      <td>Neisseria Meningitis Groups A, B, C W, And Y V...</td>\n",
       "      <td>True</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2020-11-27</td>\n",
       "      <td>2024-03-25</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Mannheim; Athens; Athens; Thessaloniki; Santia...</td>\n",
       "      <td>Germany; Greece; Greece; Greece; Spain; Spain;...</td>\n",
       "      <td>lat: 49.4891, lon: 8.46694; lat: 37.97945, lon...</td>\n",
       "      <td>Dr. med Falko Panzer Praxis fuer Kinder und Ju...</td>\n",
       "      <td>68161; 11527; 12462; 54642; 15706; 08916; 0900...</td>\n",
       "      <td>A Coruna; Barcelona; Castilla Y LEON; Madrid; ...</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>ALL</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>stopped</td>\n",
       "      <td>2023-09-01</td>\n",
       "      <td>Percentage of Participants Achieving Serum Bac...</td>\n",
       "      <td>1 month after primary vaccination 2; 1 month a...</td>\n",
       "      <td>Percentage of participants achieving hSBA tite...</td>\n",
       "      <td>hSBA Geometric Mean Titers (GMTs) for Each of ...</td>\n",
       "      <td>1 Month after primary Vaccination 2; 1 month a...</td>\n",
       "      <td>GMTs were calculated by exponentiating mean lo...</td>\n",
       "      <td>True</td>\n",
       "      <td>Meningococcal Vaccine</td>\n",
       "      <td>The Aim Of The Study Is To Describe The Safety...</td>\n",
       "      <td>None</td>\n",
       "      <td>DOUBLE</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>FACTORIAL</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>YES</td>\n",
       "      <td>0.320</td>\n",
       "      <td>0.520</td>\n",
       "      <td>1221.000</td>\n",
       "      <td>0.396</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>714 rows × 77 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    ticker       date  source             subsidiary                sponsor  \\\n",
       "0       GE 2017-11-21  listed          GE Healthcare          GE Healthcare   \n",
       "1       GE 2017-11-28  listed          GE Healthcare          GE Healthcare   \n",
       "2       GE 2017-12-01  listed          GE Healthcare          GE Healthcare   \n",
       "3       GE 2018-01-11  listed          GE Healthcare          GE Healthcare   \n",
       "4       GE 2018-01-12  listed          GE Healthcare          GE Healthcare   \n",
       "..     ...        ...     ...                    ...                    ...   \n",
       "709    PFE 2020-11-13  listed                 Pfizer                 Pfizer   \n",
       "710    PFE 2020-11-13  listed                 Pfizer                 Pfizer   \n",
       "711    PFE 2020-11-18  listed                 Pfizer                 Pfizer   \n",
       "712    PFE 2020-11-19  listed  Arena Pharmaceuticals  Arena Pharmaceuticals   \n",
       "713    PFE 2020-11-20  listed                 Pfizer                 Pfizer   \n",
       "\n",
       "        trial_id                                     official_title  \\\n",
       "0    NCT03354273  A Phase 3, Open-Label, Multicentre Study Of Fl...   \n",
       "1    NCT03757598  Epartogram Effectiveness Study: A Mixed Method...   \n",
       "2    NCT03366662  The Effect Of Frontal Electromyogram (F-Emg) A...   \n",
       "3    NCT03409146  Accuracy And Reliability Of A New Intrapartum ...   \n",
       "4    NCT03417713  Clinical Evaluation Of The Oec Elite Md For Va...   \n",
       "..           ...                                                ...   \n",
       "709  NCT04672460  A Phase 1, Open Label, Crossover Study To Esta...   \n",
       "710  NCT04635631  An Open-Label, Single-Arm, Phase 1 Study Of Ph...   \n",
       "711  NCT04642079  A Phase 3, Single-Arm Trial To Evaluate The Sa...   \n",
       "712  NCT04655599  Effect Of Olorinab On Gastrointestinal Transit...   \n",
       "713  NCT04645966  A Phase 2B Trial To Assess The Safety, Tolerab...   \n",
       "\n",
       "      sponsor_study_id                                        brief_title  \\\n",
       "0           GE-265-303  An International Study To Evaluate Diagnostic ...   \n",
       "1     ePartogram Kenya            Epartogram Effectiveness Study In Kenya   \n",
       "2               R17108  The Effect Of Frontal Electromyogram (F-Emg) A...   \n",
       "3           1404298207  Accuracy And Reliability Of Novii: Fetal Heart...   \n",
       "4    104-2017-GES-0005  Clinical Evaluation Of The Oec Elite Md For Va...   \n",
       "..                 ...                                                ...   \n",
       "709           C3441037  A Bioequivalence Study Between The Proposed An...   \n",
       "710           C3441049  Study Of Talazoparib Monotherapy In Chinese Pa...   \n",
       "711           B7471014  Safety And Immunogenicity Study Of 20Vpnc In H...   \n",
       "712         APD371-106  Effect Of Olorinab On Gastrointestinal Transit...   \n",
       "713           C3511002  A Clinical Trial To Assess The Safety, Tolerab...   \n",
       "\n",
       "                    lead_sponsor            lead_sponsor_name sponsor_type  \\\n",
       "0                  GE Healthcare                Ge Healthcare     INDUSTRY   \n",
       "1                        Jhpiego                      Jhpiego        OTHER   \n",
       "2    Tampere University Hospital  Tampere University Hospital        OTHER   \n",
       "3                  GE Healthcare                Ge Healthcare     INDUSTRY   \n",
       "4                  GE Healthcare                Ge Healthcare     INDUSTRY   \n",
       "..                           ...                          ...          ...   \n",
       "709                       Pfizer                       Pfizer     INDUSTRY   \n",
       "710                       Pfizer                       Pfizer     INDUSTRY   \n",
       "711                       Pfizer                       Pfizer     INDUSTRY   \n",
       "712        Arena Pharmaceuticals        Arena Pharmaceuticals     INDUSTRY   \n",
       "713                       Pfizer                       Pfizer     INDUSTRY   \n",
       "\n",
       "    lead_sponsor_type phase_category      study_type  enrollment_count  \\\n",
       "0            INDUSTRY        phase_3  INTERVENTIONAL               730   \n",
       "1               OTHER          other  INTERVENTIONAL               113   \n",
       "2               OTHER  not_specified   OBSERVATIONAL                 0   \n",
       "3            INDUSTRY  not_specified   OBSERVATIONAL                80   \n",
       "4            INDUSTRY  not_specified   OBSERVATIONAL                33   \n",
       "..                ...            ...             ...               ...   \n",
       "709          INDUSTRY        phase_1  INTERVENTIONAL                73   \n",
       "710          INDUSTRY        phase_1  INTERVENTIONAL                15   \n",
       "711          INDUSTRY        phase_3  INTERVENTIONAL               839   \n",
       "712          INDUSTRY        phase_1  INTERVENTIONAL                 1   \n",
       "713          INDUSTRY        phase_2  INTERVENTIONAL               326   \n",
       "\n",
       "     number_of_locations healthy_volunteers enrollment_type  \\\n",
       "0                     53              False          ACTUAL   \n",
       "1                     12               True          ACTUAL   \n",
       "2                      1              False          ACTUAL   \n",
       "3                      1               True          ACTUAL   \n",
       "4                      1              False          ACTUAL   \n",
       "..                   ...                ...             ...   \n",
       "709                   31              False          ACTUAL   \n",
       "710                    2              False          ACTUAL   \n",
       "711                   43               True          ACTUAL   \n",
       "712                    1              False          ACTUAL   \n",
       "713                   21               True          ACTUAL   \n",
       "\n",
       "    study_size_category                                 condition_keywords  \\\n",
       "0                 Large  Positron emission tomography myocardial perfus...   \n",
       "1                Medium  partograph, labor, birth, complications, newbo...   \n",
       "2                   nan                                   Electromyography   \n",
       "3                 Small                                                nan   \n",
       "4                 Small                                                nan   \n",
       "..                  ...                                                ...   \n",
       "709               Small  PARP inhibitor; Talazoparib; Talzenna; BRCA mu...   \n",
       "710               Small                                                nan   \n",
       "711               Large                                                nan   \n",
       "712               Small  Olorinab; APD371; Irritable bowel syndrome; IB...   \n",
       "713              Medium  Meningococcal Vaccine; Invasive Meningococcal ...   \n",
       "\n",
       "                      primary_condition  \\\n",
       "0         Coronary Artery Disease (Cad)   \n",
       "1                Obstetric Complication   \n",
       "2                   Anesthesia, General   \n",
       "3                           Term Labour   \n",
       "4    Interventional Vascular Conditions   \n",
       "..                                  ...   \n",
       "709               Advanced Solid Tumors   \n",
       "710                           Neoplasms   \n",
       "711                Pneumococcal Disease   \n",
       "712            Irritable Bowel Syndrome   \n",
       "713               Meningococcal Vaccine   \n",
       "\n",
       "                                     intervention_type  \\\n",
       "0                                     DRUG; DRUG; DRUG   \n",
       "1                                                OTHER   \n",
       "2                                               DEVICE   \n",
       "3                                               DEVICE   \n",
       "4                                               DEVICE   \n",
       "..                                                 ...   \n",
       "709                                   DRUG; DRUG; DRUG   \n",
       "710                                               DRUG   \n",
       "711                                         BIOLOGICAL   \n",
       "712                                         DRUG; DRUG   \n",
       "713  BIOLOGICAL; BIOLOGICAL; BIOLOGICAL; BIOLOGICAL...   \n",
       "\n",
       "                                 primary_intervention  \\\n",
       "0                                             PET MPI   \n",
       "1                                      ePartogram use   \n",
       "2    Monitoring of frontal electrical muscle activity   \n",
       "3                  Monica Novii Wireless Patch System   \n",
       "4      Fluoroscopic imaging with the OEC Elite Device   \n",
       "..                                                ...   \n",
       "709                                  TALZENNA capsule   \n",
       "710                                       talazoparib   \n",
       "711                                            20vPnC   \n",
       "712                                          Olorinab   \n",
       "713                                          MenABCWY   \n",
       "\n",
       "                                     intervention_name  \\\n",
       "0    PET MPI; SPECT MPI; Pharmacological stress agents   \n",
       "1                                       ePartogram use   \n",
       "2     Monitoring of frontal electrical muscle activity   \n",
       "3                   Monica Novii Wireless Patch System   \n",
       "4       Fluoroscopic imaging with the OEC Elite Device   \n",
       "..                                                 ...   \n",
       "709  TALZENNA capsule; Talazoparib soft gel capsule...   \n",
       "710                                        talazoparib   \n",
       "711                                             20vPnC   \n",
       "712                                  Olorinab; Placebo   \n",
       "713  MenABCWY; Bivalent rLP2086 (60-µg Dose); Bival...   \n",
       "\n",
       "                         intervention_arm_group_labels  \\\n",
       "0                                              1; 1; 1   \n",
       "1                                           ePartogram   \n",
       "2                                                 None   \n",
       "3                                        Term Patients   \n",
       "4                                         All Subjects   \n",
       "..                                                 ...   \n",
       "709  Sequence 1; Sequence 2; Sequence 1; Sequence 2...   \n",
       "710                                        talazoparib   \n",
       "711  Cohort 1: =>15 through 23 months of age; Cohor...   \n",
       "712  Olorinab, Then Placebo; Placebo, Then Olorinab...   \n",
       "713  Blinded: MenABCWY and placebo with SLP or TLP ...   \n",
       "\n",
       "                              intervention_description  \\\n",
       "0    Flurpiridaz (18F) Injection. All Participants ...   \n",
       "1    Electronic Partograph Based On Who Standard Pa...   \n",
       "2    Continuous Monitoring Of Frontal Electrical Mu...   \n",
       "3    The Monica Novii Wireless Patch System Is A Tr...   \n",
       "4    Vascular, Gastrointestinal (Gi), Urology Or Pa...   \n",
       "..                                                 ...   \n",
       "709  Current Commercial Talazoparib Formulation 1 M...   \n",
       "710  Talazoparib Will Be Administered Orally On A C...   \n",
       "711           20-Valent Pneumococcal Conjugate Vaccine   \n",
       "712  Olorinab Tablet By Mouth, 3 Times A Day For 4 ...   \n",
       "713  Neisseria Meningitis Groups A, B, C W, And Y V...   \n",
       "\n",
       "    has_data_monitoring_committee responsible_party_investigator_affiliation  \\\n",
       "0                            True                                       None   \n",
       "1                           False                                       None   \n",
       "2                           False                                       None   \n",
       "3                           False                                       None   \n",
       "4                           False                                       None   \n",
       "..                            ...                                        ...   \n",
       "709                          None                                       None   \n",
       "710                         False                                       None   \n",
       "711                          True                                       None   \n",
       "712                         False                                       None   \n",
       "713                          True                                       None   \n",
       "\n",
       "    responsible_party_investigator_title responsible_party_investigator_name  \\\n",
       "0                                   None                                None   \n",
       "1                                   None                                None   \n",
       "2                                   None                                None   \n",
       "3                                   None                                None   \n",
       "4                                   None                                None   \n",
       "..                                   ...                                 ...   \n",
       "709                                 None                                None   \n",
       "710                                 None                                None   \n",
       "711                                 None                                None   \n",
       "712                                 None                                None   \n",
       "713                                 None                                None   \n",
       "\n",
       "    first_posted_date last_update_posted_date start_date  \\\n",
       "0          2017-11-27              2023-07-12 2018-06-05   \n",
       "1          2018-11-29              2019-12-11 2016-08-01   \n",
       "2          2017-12-08              2020-03-12        NaT   \n",
       "3          2018-01-24              2021-02-09 2014-05-28   \n",
       "4          2018-01-31              2018-11-29        NaT   \n",
       "..                ...                     ...        ...   \n",
       "709        2020-12-17              2024-09-25        NaT   \n",
       "710        2020-11-19              2023-10-10        NaT   \n",
       "711        2020-11-24              2024-01-22        NaT   \n",
       "712        2020-12-07              2021-05-17 2021-01-29   \n",
       "713        2020-11-27              2024-03-25        NaT   \n",
       "\n",
       "    study_completion_date primary_completion_date  \\\n",
       "0              2022-05-05              2022-05-05   \n",
       "1              2017-05-30              2017-05-30   \n",
       "2                     NaT                     NaT   \n",
       "3              2017-02-13              2017-02-13   \n",
       "4                     NaT                     NaT   \n",
       "..                    ...                     ...   \n",
       "709                   NaT                     NaT   \n",
       "710                   NaT                     NaT   \n",
       "711                   NaT                     NaT   \n",
       "712            2021-04-13              2021-04-13   \n",
       "713                   NaT                     NaT   \n",
       "\n",
       "                                  study_locations_city  \\\n",
       "0    Birmingham; Los Angeles; Los Angeles; Los Ange...   \n",
       "1    Kisumu; Kisumu; Kisumu; Kisumu; Kisumu; Kisumu...   \n",
       "2                                              Tampere   \n",
       "3                                               Tucson   \n",
       "4                                             Hamilton   \n",
       "..                                                 ...   \n",
       "709  Encinitas; Los Angeles; Los Angeles; San Marco...   \n",
       "710                                 Changchun; Beijing   \n",
       "711  Fayetteville; Jonesboro; Jonesboro; San Diego;...   \n",
       "712                                          Rochester   \n",
       "713  Mannheim; Athens; Athens; Thessaloniki; Santia...   \n",
       "\n",
       "                               study_locations_country  \\\n",
       "0    United States; United States; United States; U...   \n",
       "1    Kenya; Kenya; Kenya; Kenya; Kenya; Kenya; Keny...   \n",
       "2                                              Finland   \n",
       "3                                        United States   \n",
       "4                                               Canada   \n",
       "..                                                 ...   \n",
       "709  United States; United States; United States; U...   \n",
       "710                                       China; China   \n",
       "711  United States; United States; United States; U...   \n",
       "712                                      United States   \n",
       "713  Germany; Greece; Greece; Greece; Spain; Spain;...   \n",
       "\n",
       "                              study_locations_geopoint  \\\n",
       "0    lat: 33.52066, lon: -86.80249; lat: 34.05223, ...   \n",
       "1    lat: -0.10221, lon: 34.76171; lat: -0.10221, l...   \n",
       "2                         lat: 61.49911, lon: 23.78712   \n",
       "3                       lat: 32.22174, lon: -110.92648   \n",
       "4                        lat: 43.25011, lon: -79.84963   \n",
       "..                                                 ...   \n",
       "709  lat: 33.03699, lon: -117.29198; lat: 34.05223,...   \n",
       "710  lat: 43.88, lon: 125.32278; lat: 39.9075, lon:...   \n",
       "711  lat: 36.06258, lon: -94.15743; lat: 35.8423, l...   \n",
       "712                       lat: 44.02163, lon: -92.4699   \n",
       "713  lat: 49.4891, lon: 8.46694; lat: 37.97945, lon...   \n",
       "\n",
       "                              study_locations_facility  \\\n",
       "0    Vascular Biology and Hypertension Program, Uni...   \n",
       "1    Ahero Hospital; Kisumu Hospital; Kombewa Healt...   \n",
       "2                          Tampere University Hospital   \n",
       "3                 University of Arizona Medical Center   \n",
       "4                            Hamilton General Hospital   \n",
       "..                                                 ...   \n",
       "709  California Cancer Associates for Research and ...   \n",
       "710  Jilin Cancer Hospital; Cancer Hospital, Chines...   \n",
       "711  Northwest Arkansas Pediatrics; The Children's ...   \n",
       "712                                        Mayo Clinic   \n",
       "713  Dr. med Falko Panzer Praxis fuer Kinder und Ju...   \n",
       "\n",
       "                                   study_locations_zip  \\\n",
       "0    35294; 90024; 90033; 90073; 92161; 94107; 9040...   \n",
       "1                                                 None   \n",
       "2                                                33521   \n",
       "3                                                85724   \n",
       "4                                              L8L 2X2   \n",
       "..                                                 ...   \n",
       "709  92024; 90048; 90048; 92069; 06510; 06510; 0651...   \n",
       "710                                     130000; 100021   \n",
       "711  72703; 72401; 72401; 92123-1881; 33126; 33184;...   \n",
       "712                                              55905   \n",
       "713  68161; 11527; 12462; 54642; 15706; 08916; 0900...   \n",
       "\n",
       "                                 study_locations_state  \\\n",
       "0    Alabama; California; California; California; C...   \n",
       "1                                                 None   \n",
       "2                                                 None   \n",
       "3                                              Arizona   \n",
       "4                                              Ontario   \n",
       "..                                                 ...   \n",
       "709  California; California; California; California...   \n",
       "710                                              Jilin   \n",
       "711  Arkansas; Arkansas; Arkansas; California; Flor...   \n",
       "712                                          Minnesota   \n",
       "713  A Coruna; Barcelona; Castilla Y LEON; Madrid; ...   \n",
       "\n",
       "           standard_age_groups     sex  minimum_age  maximum_age  \\\n",
       "0           ADULT; OLDER_ADULT     ALL           18         <NA>   \n",
       "1    CHILD; ADULT; OLDER_ADULT  FEMALE         <NA>         <NA>   \n",
       "2           ADULT; OLDER_ADULT     ALL           18         <NA>   \n",
       "3           ADULT; OLDER_ADULT  FEMALE           18         <NA>   \n",
       "4           ADULT; OLDER_ADULT     ALL           18           85   \n",
       "..                         ...     ...          ...          ...   \n",
       "709         ADULT; OLDER_ADULT     ALL           18           70   \n",
       "710         ADULT; OLDER_ADULT     ALL           18         <NA>   \n",
       "711                      CHILD     ALL            1           17   \n",
       "712         ADULT; OLDER_ADULT     ALL           18           70   \n",
       "713                      CHILD     ALL            0            0   \n",
       "\n",
       "    overall_status status_category status_verified_date  \\\n",
       "0        COMPLETED       completed           2023-06-01   \n",
       "1        COMPLETED       completed           2019-12-01   \n",
       "2        WITHDRAWN         stopped           2020-03-01   \n",
       "3        COMPLETED       completed           2021-02-01   \n",
       "4        COMPLETED       completed           2018-10-01   \n",
       "..             ...             ...                  ...   \n",
       "709      COMPLETED       completed           2024-06-01   \n",
       "710      COMPLETED       completed           2022-12-01   \n",
       "711      COMPLETED       completed           2024-01-01   \n",
       "712     TERMINATED         stopped           2021-05-01   \n",
       "713     TERMINATED         stopped           2023-09-01   \n",
       "\n",
       "                             primary_outcomes_measures  \\\n",
       "0    Sensitivity and Specificity of Flurpiridaz (18...   \n",
       "1    Percent of partographs showing fetal/newborn w...   \n",
       "2    Burst suppression electroencephalogram data wi...   \n",
       "3    Fetal Heart Rate (FHR) Positive Percentage Agr...   \n",
       "4    Image Guidance Adequacy Collected Via Survey Q...   \n",
       "..                                                 ...   \n",
       "709  Area Under the Plasma Concentration-Time Profi...   \n",
       "710  Maximum Observed Concentration (Cmax) of Talaz...   \n",
       "711  Percentage of Participants Reporting Prompted ...   \n",
       "712  Colonic transit geometric center after consump...   \n",
       "713  Percentage of Participants Achieving Serum Bac...   \n",
       "\n",
       "                           primary_outcomes_timeframes  \\\n",
       "0                                        Up to 60 days   \n",
       "1    All partographs within the 6 month interventio...   \n",
       "2                                              One day   \n",
       "3       through study completion, an average of 1 year   \n",
       "4    Approximately 2 months (duration of subject en...   \n",
       "..                                                 ...   \n",
       "709  Serial blood sample (4 mL) each was collected ...   \n",
       "710  Pre-dose and 0.5 hours, 1 hour, 2 hours, 4 hou...   \n",
       "711  Within 7 days after vaccination on Day 1; With...   \n",
       "712  up to 24 hours 30 minutes after consumption of...   \n",
       "713  1 month after primary vaccination 2; 1 month a...   \n",
       "\n",
       "                         primary_outcomes_descriptions  \\\n",
       "0    Sensitivity was defined as true positives (TP)...   \n",
       "1    Percent of partographs with a suboptimal fetal...   \n",
       "2                                          Visible EMG   \n",
       "3    PPA(%)=(a/(a+C))x100, where \"a\" represents the...   \n",
       "4    Number of participants whose procedures were c...   \n",
       "..                                                 ...   \n",
       "709  AUC24 was defined as area under the plasma con...   \n",
       "710  Maximum plasma concentration of talazoparib af...   \n",
       "711  Local reactions included redness, swelling and...   \n",
       "712                                               None   \n",
       "713  Percentage of participants achieving hSBA tite...   \n",
       "\n",
       "                           secondary_outcomes_measures  \\\n",
       "0    Sensitivity and Specificity of Flurpiridaz (18...   \n",
       "1    Percent of partographs with a suboptimal mater...   \n",
       "2                                                 None   \n",
       "3    Mean Percentage FHR Equivalence; Uterine Activ...   \n",
       "4    Number of Investigator Procedure Surveys Asses...   \n",
       "..                                                 ...   \n",
       "709  Apparent Clearance After Oral Dose (CL/F) of T...   \n",
       "710  Number of Participants With Treatment-Emergent...   \n",
       "711  Percentage of Participants With Predefined Lev...   \n",
       "712  Colonic transit geometric center after consump...   \n",
       "713  hSBA Geometric Mean Titers (GMTs) for Each of ...   \n",
       "\n",
       "                         secondary_outcomes_timeframes  \\\n",
       "0    Up to 60 days; Up to 60 days; Up to 60 days; U...   \n",
       "1    All partographs within the 6 month interventio...   \n",
       "2                                                 None   \n",
       "3    through study completion, an average of 1 year...   \n",
       "4    Approximately 2 months (duration of subject en...   \n",
       "..                                                 ...   \n",
       "709  Serial blood sample (4 mL) each was collected ...   \n",
       "710  Baseline (the latest non-missing value prior t...   \n",
       "711  At 1 Month after vaccination on Day 1; Before ...   \n",
       "712  up to 48 hours 30 minutes after consumption of...   \n",
       "713  1 Month after primary Vaccination 2; 1 month a...   \n",
       "\n",
       "                       secondary_outcomes_descriptions  has_results  \\\n",
       "0    Sensitivity:TP/(TP+FN). TP:participants with a...         True   \n",
       "1    Percent of partographs with a suboptimal mater...        False   \n",
       "2                                                 None        False   \n",
       "3    The 2 second output FHR data when both the pre...        False   \n",
       "4    To collect image data acquired during clinical...         True   \n",
       "..                                                 ...          ...   \n",
       "709  Apparent Clearance After Oral Dose (CL/F) was ...         True   \n",
       "710  An adverse event (AE) was any untoward medical...         True   \n",
       "711  Pneumococcal serotype-specific IgG concentrati...         True   \n",
       "712  Safety will be assessed by monitoring adverse ...        False   \n",
       "713  GMTs were calculated by exponentiating mean lo...         True   \n",
       "\n",
       "                                            conditions  \\\n",
       "0                        Coronary Artery Disease (Cad)   \n",
       "1    Obstetric Complication; Obstetric Labor Compli...   \n",
       "2                                  Anesthesia, General   \n",
       "3                                          Term Labour   \n",
       "4                   Interventional Vascular Conditions   \n",
       "..                                                 ...   \n",
       "709  Advanced Solid Tumors; Solid Tumors; Ovarian C...   \n",
       "710                                          Neoplasms   \n",
       "711                               Pneumococcal Disease   \n",
       "712                           Irritable Bowel Syndrome   \n",
       "713                              Meningococcal Vaccine   \n",
       "\n",
       "                                         brief_summary  \\\n",
       "0    This Is A Phase 3, Prospective, Open-Label, In...   \n",
       "1    Quasi-Experimental Study To Evaluate Whether C...   \n",
       "2    This Study Evaluates The Effect Of Frontal Emg...   \n",
       "3    Accuracy And Reliability Of The Novii Device (...   \n",
       "4    The Purpose Of This Study Is To Collect Feedba...   \n",
       "..                                                 ...   \n",
       "709  This Will Be A Phase 1, Open Label, 2-Sequence...   \n",
       "710  A Phase1 Study To Evaluate The Pk (Single Dose...   \n",
       "711  This Study Is Designed To Evaluate The Safety ...   \n",
       "712  A Phase 1B Study To Determine The Effect Of Or...   \n",
       "713  The Aim Of The Study Is To Describe The Safety...   \n",
       "\n",
       "                                  detailed_description masking  \\\n",
       "0                                                 None    NONE   \n",
       "1    The Epartogram Is An Electronic Version Of The...    NONE   \n",
       "2    This Is An Academic Observational Study, Where...    None   \n",
       "3    The Study Is Being Done To Test The Performanc...    None   \n",
       "4                                                 None    None   \n",
       "..                                                 ...     ...   \n",
       "709                                               None    NONE   \n",
       "710                                               None    NONE   \n",
       "711                                               None    NONE   \n",
       "712  This Is A Single-Center, Randomized, Crossover...  DOUBLE   \n",
       "713                                               None  DOUBLE   \n",
       "\n",
       "         allocation intervention_model           primary_purpose  \\\n",
       "0                NA       SINGLE_GROUP                DIAGNOSTIC   \n",
       "1    NON_RANDOMIZED           PARALLEL  HEALTH_SERVICES_RESEARCH   \n",
       "2              None               None                      None   \n",
       "3              None               None                      None   \n",
       "4              None               None                      None   \n",
       "..              ...                ...                       ...   \n",
       "709      RANDOMIZED          CROSSOVER                 TREATMENT   \n",
       "710              NA       SINGLE_GROUP                 TREATMENT   \n",
       "711  NON_RANDOMIZED       SINGLE_GROUP                PREVENTION   \n",
       "712      RANDOMIZED          CROSSOVER             BASIC_SCIENCE   \n",
       "713      RANDOMIZED          FACTORIAL                PREVENTION   \n",
       "\n",
       "     has_expanded_access  study_duration_days  trial_duration  \\\n",
       "0                  False                 1430        1430.000   \n",
       "1                  False                  302         302.000   \n",
       "2                  False                 <NA>             NaN   \n",
       "3                  False                  992         992.000   \n",
       "4                  False                 <NA>             NaN   \n",
       "..                   ...                  ...             ...   \n",
       "709                False                 <NA>             NaN   \n",
       "710                False                 <NA>             NaN   \n",
       "711                False                 <NA>             NaN   \n",
       "712                False                   74          74.000   \n",
       "713                False                 <NA>             NaN   \n",
       "\n",
       "            references_type  \\\n",
       "0                   DERIVED   \n",
       "1    BACKGROUND; BACKGROUND   \n",
       "2                      None   \n",
       "3                      None   \n",
       "4                      None   \n",
       "..                      ...   \n",
       "709                    None   \n",
       "710                    None   \n",
       "711                    None   \n",
       "712                    None   \n",
       "713                    None   \n",
       "\n",
       "                                   references_citation references_pmid  \\\n",
       "0    Bourque JM, Hanson CA, Agostini D, Bateman TM,...        33521873   \n",
       "1    Managing complications in pregnancy and childb...        29743032   \n",
       "2                                                 None            None   \n",
       "3                                                 None            None   \n",
       "4                                                 None            None   \n",
       "..                                                 ...             ...   \n",
       "709                                               None            None   \n",
       "710                                               None            None   \n",
       "711                                               None            None   \n",
       "712                                               None            None   \n",
       "713                                               None            None   \n",
       "\n",
       "                          collaborators_name collaborators_class ipd_sharing  \\\n",
       "0    Pharmaceutical Product Development, LLC             UNKNOWN        None   \n",
       "1                              GE Healthcare            INDUSTRY   UNDECIDED   \n",
       "2                              GE Healthcare            INDUSTRY          NO   \n",
       "3                                       None                None          NO   \n",
       "4                                       None                None        None   \n",
       "..                                       ...                 ...         ...   \n",
       "709                                     None                None          NO   \n",
       "710                                     None                None          NO   \n",
       "711                                     None                None         YES   \n",
       "712                                     None                None          NO   \n",
       "713                                     None                None         YES   \n",
       "\n",
       "     success_prediction  economic_effect  duration_prediction  \\\n",
       "0                 0.970            0.620             1430.000   \n",
       "1                 0.940            0.570              302.000   \n",
       "2                 0.100            0.050              832.000   \n",
       "3                 0.320            0.050              992.000   \n",
       "4                 0.830            0.450              321.000   \n",
       "..                  ...              ...                  ...   \n",
       "709               0.950            0.810             1412.000   \n",
       "710               0.940            0.810             1061.000   \n",
       "711               0.950            0.880              889.000   \n",
       "712               0.160            0.510               74.000   \n",
       "713               0.320            0.520             1221.000   \n",
       "\n",
       "     success_composite     class  \n",
       "0                0.828  INDUSTRY  \n",
       "1                0.743  INDUSTRY  \n",
       "2                0.061  INDUSTRY  \n",
       "3                0.188  INDUSTRY  \n",
       "4                0.636  INDUSTRY  \n",
       "..                 ...       ...  \n",
       "709              0.838  INDUSTRY  \n",
       "710              0.836  INDUSTRY  \n",
       "711              0.913  INDUSTRY  \n",
       "712              0.288  INDUSTRY  \n",
       "713              0.396  INDUSTRY  \n",
       "\n",
       "[714 rows x 77 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_apps"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>date</th>\n",
       "      <th>source</th>\n",
       "      <th>subsidiary</th>\n",
       "      <th>sponsor</th>\n",
       "      <th>trial_id</th>\n",
       "      <th>official_title</th>\n",
       "      <th>sponsor_study_id</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>lead_sponsor_name</th>\n",
       "      <th>sponsor_type</th>\n",
       "      <th>lead_sponsor_type</th>\n",
       "      <th>phase_category</th>\n",
       "      <th>study_type</th>\n",
       "      <th>enrollment_count</th>\n",
       "      <th>number_of_locations</th>\n",
       "      <th>healthy_volunteers</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>study_size_category</th>\n",
       "      <th>condition_keywords</th>\n",
       "      <th>primary_condition</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>primary_intervention</th>\n",
       "      <th>intervention_name</th>\n",
       "      <th>intervention_arm_group_labels</th>\n",
       "      <th>intervention_description</th>\n",
       "      <th>has_data_monitoring_committee</th>\n",
       "      <th>responsible_party_investigator_affiliation</th>\n",
       "      <th>responsible_party_investigator_title</th>\n",
       "      <th>responsible_party_investigator_name</th>\n",
       "      <th>first_posted_date</th>\n",
       "      <th>last_update_posted_date</th>\n",
       "      <th>start_date</th>\n",
       "      <th>study_completion_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>study_locations_city</th>\n",
       "      <th>study_locations_country</th>\n",
       "      <th>study_locations_geopoint</th>\n",
       "      <th>study_locations_facility</th>\n",
       "      <th>study_locations_zip</th>\n",
       "      <th>study_locations_state</th>\n",
       "      <th>standard_age_groups</th>\n",
       "      <th>sex</th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>maximum_age</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>status_category</th>\n",
       "      <th>status_verified_date</th>\n",
       "      <th>primary_outcomes_measures</th>\n",
       "      <th>primary_outcomes_timeframes</th>\n",
       "      <th>primary_outcomes_descriptions</th>\n",
       "      <th>secondary_outcomes_measures</th>\n",
       "      <th>secondary_outcomes_timeframes</th>\n",
       "      <th>secondary_outcomes_descriptions</th>\n",
       "      <th>has_results</th>\n",
       "      <th>conditions</th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>masking</th>\n",
       "      <th>allocation</th>\n",
       "      <th>intervention_model</th>\n",
       "      <th>primary_purpose</th>\n",
       "      <th>has_expanded_access</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>trial_duration</th>\n",
       "      <th>references_type</th>\n",
       "      <th>references_citation</th>\n",
       "      <th>references_pmid</th>\n",
       "      <th>collaborators_name</th>\n",
       "      <th>collaborators_class</th>\n",
       "      <th>ipd_sharing</th>\n",
       "      <th>success_prediction</th>\n",
       "      <th>economic_effect</th>\n",
       "      <th>duration_prediction</th>\n",
       "      <th>success_composite</th>\n",
       "      <th>class</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>AAPL</td>\n",
       "      <td>2018-02-02</td>\n",
       "      <td>listed</td>\n",
       "      <td>Apple  Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>NCT03426280</td>\n",
       "      <td>Activity Therapy After Kidney Transplant: A Pi...</td>\n",
       "      <td>44663</td>\n",
       "      <td>Activity Therapy After Kidney Transplant</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>13</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Kidney Transplant; Complications</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Apple Watch Series 1</td>\n",
       "      <td>Apple Watch Series 1</td>\n",
       "      <td>Apple Watch</td>\n",
       "      <td>Clinic Pharmacists Will Issue Apple Watches To...</td>\n",
       "      <td>False</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Clinical Assistant Professor</td>\n",
       "      <td>Xingxing Shelley Cheng</td>\n",
       "      <td>2018-02-08</td>\n",
       "      <td>2023-06-27</td>\n",
       "      <td>2018-05-01</td>\n",
       "      <td>2020-01-31</td>\n",
       "      <td>2020-01-31</td>\n",
       "      <td>Palo Alto</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 37.44188, lon: -122.14302</td>\n",
       "      <td>Stanford Hospital and Clinic</td>\n",
       "      <td>94304</td>\n",
       "      <td>California</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>stopped</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>Activity Level (daily caloric consumption); % ...</td>\n",
       "      <td>1 year; 1st year of transplant</td>\n",
       "      <td>None</td>\n",
       "      <td>Weight; Hemoglobin A1c</td>\n",
       "      <td>1st year of transplant; 1st year of transplant</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Kidney Transplant; Complications</td>\n",
       "      <td>To Combat Post-Transplant Weight Gain, We Seek...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>False</td>\n",
       "      <td>640</td>\n",
       "      <td>640.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.110</td>\n",
       "      <td>0.050</td>\n",
       "      <td>640.000</td>\n",
       "      <td>0.069</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>AAPL</td>\n",
       "      <td>2018-02-27</td>\n",
       "      <td>listed</td>\n",
       "      <td>Apple  Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>NCT03492554</td>\n",
       "      <td>Electrocardiogram Clinical Validation Study</td>\n",
       "      <td>099-11774</td>\n",
       "      <td>Electrocardiogram Clinical Validation Study</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>602</td>\n",
       "      <td>5</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Large</td>\n",
       "      <td>nan</td>\n",
       "      <td>Atrial Fibrillation</td>\n",
       "      <td>OTHER; DEVICE</td>\n",
       "      <td>1-Lead ECG</td>\n",
       "      <td>1-Lead ECG; 12-Lead ECG</td>\n",
       "      <td>Atrial fibrillation (AF); Normal Sinus Rhythm ...</td>\n",
       "      <td>All Participants Will Record Three Single-Lead...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-04-10</td>\n",
       "      <td>2020-12-03</td>\n",
       "      <td>2018-03-12</td>\n",
       "      <td>2018-05-14</td>\n",
       "      <td>2018-05-14</td>\n",
       "      <td>Miami; Orlando; The Villages; Overland Park; S...</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 25.77427, lon: -80.19366; lat: 28.53834, ...</td>\n",
       "      <td>QPS; BioClinicia- Orlando; BioClinica- The Vil...</td>\n",
       "      <td>33143; 32806; 32162; 66211; 55102</td>\n",
       "      <td>Florida; Florida; Florida; Kansas; Minnesota</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>22</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2020-11-01</td>\n",
       "      <td>Number of Participants With Software's Rhythm ...</td>\n",
       "      <td>1 Day; 1 Day</td>\n",
       "      <td>Specificity of rhythm classification; Sensitiv...</td>\n",
       "      <td>Number of Participants With Software's Ability...</td>\n",
       "      <td>1 Day; 1 Day; 1 Day</td>\n",
       "      <td>Number of ECGs that pass a visual overlay; Dif...</td>\n",
       "      <td>True</td>\n",
       "      <td>Atrial Fibrillation</td>\n",
       "      <td>The Purpose Of The Study Is To Confirm The Sof...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>BASIC_SCIENCE</td>\n",
       "      <td>False</td>\n",
       "      <td>63</td>\n",
       "      <td>63.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Iqvia Pty Ltd</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.930</td>\n",
       "      <td>0.660</td>\n",
       "      <td>63.000</td>\n",
       "      <td>0.774</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>AAPL</td>\n",
       "      <td>2018-11-21</td>\n",
       "      <td>listed</td>\n",
       "      <td>Apple  Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>NCT03760796</td>\n",
       "      <td>The Johns Hopkins Myocardial Infarction, Combi...</td>\n",
       "      <td>IRB00099938</td>\n",
       "      <td>Myocardial Infarction, Combined-Device, Recove...</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>200</td>\n",
       "      <td>4</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Medium</td>\n",
       "      <td>readmission; cardiovascular disease prevention...</td>\n",
       "      <td>Acute Myocardial Infarction</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Corrie Health Digital Platform</td>\n",
       "      <td>Corrie Health Digital Platform</td>\n",
       "      <td>Corrie Health Digital Platform group</td>\n",
       "      <td>The Corrie Health Digital Platform Consists Of...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2018-11-30</td>\n",
       "      <td>2021-07-29</td>\n",
       "      <td>2016-10-01</td>\n",
       "      <td>2019-12-17</td>\n",
       "      <td>2019-12-17</td>\n",
       "      <td>Baltimore; Baltimore; Boston; Reading</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 39.29038, lon: -76.61219; lat: 39.29038, ...</td>\n",
       "      <td>Johns Hopkins Bayview Medical Center; Johns Ho...</td>\n",
       "      <td>21224; 21287; 02114; 19611</td>\n",
       "      <td>Maryland; Maryland; Massachusetts; Pennsylvania</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>Number of Participants Readmitted Within 30-da...</td>\n",
       "      <td>30-days post hospital discharge</td>\n",
       "      <td>Number of participants readmitted within 30-da...</td>\n",
       "      <td>Cost-effectiveness as Assessed by a Markov Mod...</td>\n",
       "      <td>30 days post hospital discharge; 3 days post h...</td>\n",
       "      <td>We estimated typical costs associated with rea...</td>\n",
       "      <td>True</td>\n",
       "      <td>Acute Myocardial Infarction; Coronary Artery D...</td>\n",
       "      <td>Unplanned Readmissions After Hospitalization F...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>False</td>\n",
       "      <td>1172</td>\n",
       "      <td>1172.000</td>\n",
       "      <td>BACKGROUND; BACKGROUND; BACKGROUND; RESULT; RE...</td>\n",
       "      <td>Spaulding EM, Marvel FA, Lee MA, Yang WE, Demo...</td>\n",
       "      <td>31043065; 31094337; 31758761; 33999374; 329642...</td>\n",
       "      <td>Apple Inc.; iHealth</td>\n",
       "      <td>INDUSTRY; OTHER</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.560</td>\n",
       "      <td>1172.000</td>\n",
       "      <td>0.735</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>AAPL</td>\n",
       "      <td>2018-12-06</td>\n",
       "      <td>listed</td>\n",
       "      <td>Apple  Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>NCT03769207</td>\n",
       "      <td>Evaluation Of The Use Of Apple Watch Features ...</td>\n",
       "      <td>1.2</td>\n",
       "      <td>Evaluation Of The Use Of Apple Watch Features ...</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>17</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Atrial Fibrillation</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>Ambulatory ECG</td>\n",
       "      <td>Ambulatory ECG</td>\n",
       "      <td>Ambulatory ECG</td>\n",
       "      <td>Eligible Participants Are Asked To Wear The Am...</td>\n",
       "      <td>False</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Assistant Professor of Medicine (Cardiovascula...</td>\n",
       "      <td>Marco Perez</td>\n",
       "      <td>2018-12-07</td>\n",
       "      <td>2020-10-20</td>\n",
       "      <td>2018-12-08</td>\n",
       "      <td>2019-08-20</td>\n",
       "      <td>2019-07-05</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 37.42411, lon: -122.16608</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>94304</td>\n",
       "      <td>California</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>22</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2020-09-01</td>\n",
       "      <td>Atrial Fibrillation or Atrial Flutter (AF) of ...</td>\n",
       "      <td>During ambulatory ECG Monitoring (up to 8 days)</td>\n",
       "      <td>Detected on ambulatory ECG patch monitor for a...</td>\n",
       "      <td>Arrhythmias Other Than AF; Self-reported Conta...</td>\n",
       "      <td>During ambulatory ECG Monitoring (up to 8 days...</td>\n",
       "      <td>Detected on an ambulatory ECG patch monitor fo...</td>\n",
       "      <td>True</td>\n",
       "      <td>Atrial Fibrillation; Arrhythmias, Cardiac; Atr...</td>\n",
       "      <td>This Post-Marketing Study Is Conducted To Char...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>False</td>\n",
       "      <td>255</td>\n",
       "      <td>255.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.860</td>\n",
       "      <td>0.530</td>\n",
       "      <td>255.000</td>\n",
       "      <td>0.683</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>AAPL</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>listed</td>\n",
       "      <td>Apple  Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>NCT04198194</td>\n",
       "      <td>Apple Heart &amp; Movement Study</td>\n",
       "      <td>2019P002257</td>\n",
       "      <td>Apple Heart &amp; Movement Study</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>Apple Inc.</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>500000</td>\n",
       "      <td>1</td>\n",
       "      <td>None</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Very Large</td>\n",
       "      <td>nan</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>DIAGNOSTIC_TEST</td>\n",
       "      <td>Predictors of events</td>\n",
       "      <td>Predictors of events</td>\n",
       "      <td>Participants with events</td>\n",
       "      <td>Apple Heart \\&amp; Movement Study In Apple Researc...</td>\n",
       "      <td>True</td>\n",
       "      <td>Brigham and Women's Hospital</td>\n",
       "      <td>Principal Investigator</td>\n",
       "      <td>Calum A. Macrae</td>\n",
       "      <td>2019-12-13</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2024-11-14</td>\n",
       "      <td>2024-11-14</td>\n",
       "      <td>Boston</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 42.35843, lon: -71.05977</td>\n",
       "      <td>Brigham and Women's Hospital</td>\n",
       "      <td>02115</td>\n",
       "      <td>Massachusetts</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>other</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>Number of Participants with Chronic Disease Ev...</td>\n",
       "      <td>quarterly (every 90 days) through study comple...</td>\n",
       "      <td>Change in number of participants with incident...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>This Study Will Look For Factors That Affect H...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>American Heart Association</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.280</td>\n",
       "      <td>0.050</td>\n",
       "      <td>618.000</td>\n",
       "      <td>0.169</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1477</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2024-12-10</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT06733337</td>\n",
       "      <td>Special Investigation Of Talzenna Capsules - S...</td>\n",
       "      <td>C3441050</td>\n",
       "      <td>A Study To Learn About The Safety Of Talzenna ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>104</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Medium</td>\n",
       "      <td>BRCA mutation-positive; metastatic castration-...</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>nan</td>\n",
       "      <td>nan</td>\n",
       "      <td>nan</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2024-12-13</td>\n",
       "      <td>2024-12-13</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CHILD; ADULT; OLDER_ADULT</td>\n",
       "      <td>MALE</td>\n",
       "      <td>0</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>active</td>\n",
       "      <td>2024-12-01</td>\n",
       "      <td>Incidence of adverse drug reactions</td>\n",
       "      <td>Up to 52 weeks</td>\n",
       "      <td>For adverse drug reactions corresponding to my...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Prostate Cancer</td>\n",
       "      <td>The Purpose Of This Study Is To Learn About Th...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.290</td>\n",
       "      <td>0.060</td>\n",
       "      <td>733.000</td>\n",
       "      <td>0.177</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1478</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2024-12-11</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT06735742</td>\n",
       "      <td>Talzenna Capsules Special Investigation - Inve...</td>\n",
       "      <td>C3441045</td>\n",
       "      <td>A Study To Learn About The Safety Of Talzenna ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>37</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Small</td>\n",
       "      <td>BRCA mutation-positive and HER2-negative; unre...</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>nan</td>\n",
       "      <td>nan</td>\n",
       "      <td>nan</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2024-12-16</td>\n",
       "      <td>2024-12-16</td>\n",
       "      <td>2025-01-31</td>\n",
       "      <td>2031-07-25</td>\n",
       "      <td>2031-07-25</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CHILD; ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>0</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>active</td>\n",
       "      <td>2024-12-01</td>\n",
       "      <td>Incidence of adverse drug reactions</td>\n",
       "      <td>Up to 52 weeks</td>\n",
       "      <td>For adverse drug reactions corresponding to my...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>The Purpose Of This Study Is To Learn About Th...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>2366</td>\n",
       "      <td>2366.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.260</td>\n",
       "      <td>0.040</td>\n",
       "      <td>2417.000</td>\n",
       "      <td>0.139</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1479</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2024-12-16</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT06743334</td>\n",
       "      <td>Secondary Databased Post-Marketing Surveillanc...</td>\n",
       "      <td>C4591056</td>\n",
       "      <td>Secondary Databased Post-Marketing Surveillanc...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>10890000</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Very Large</td>\n",
       "      <td>COVID-19 Vaccines; Safety; SARS-CoV-2</td>\n",
       "      <td>Covid-19</td>\n",
       "      <td>BIOLOGICAL; BIOLOGICAL; BIOLOGICAL</td>\n",
       "      <td>Tozinameran (BNT162b2)</td>\n",
       "      <td>Tozinameran (BNT162b2); Tozinameran (BNT162b2)...</td>\n",
       "      <td>All primary series recipients using monovalent...</td>\n",
       "      <td>1. 12 Years Or Older\\n\\n   * Primary Series: 2...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2024-12-19</td>\n",
       "      <td>2024-12-19</td>\n",
       "      <td>2025-05-28</td>\n",
       "      <td>2025-05-28</td>\n",
       "      <td>2025-05-28</td>\n",
       "      <td>Seoul</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>lat: 37.566, lon: 126.9784</td>\n",
       "      <td>Pfizer Korea</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CHILD; ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>0</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>active</td>\n",
       "      <td>2024-12-01</td>\n",
       "      <td>Frequency of Adverse Events of Special Interes...</td>\n",
       "      <td>Up to 270 days after vaccination; Up to 270 da...</td>\n",
       "      <td>Measure of Occurrence (Cohort design) The freq...</td>\n",
       "      <td>Frequency of Severe COVID-19 Outcomes; Inciden...</td>\n",
       "      <td>Up to 150 days after vaccination; Up to 150 da...</td>\n",
       "      <td>The frequency of severe COVID-19 outcomes incl...</td>\n",
       "      <td>False</td>\n",
       "      <td>Covid-19; Sars-Cov-2</td>\n",
       "      <td>This Study Is To Assess The Post-Marketing Saf...</td>\n",
       "      <td>This Study Is A Retrospective, Non-Interventio...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>0</td>\n",
       "      <td>0.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.280</td>\n",
       "      <td>0.050</td>\n",
       "      <td>163.000</td>\n",
       "      <td>0.177</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1480</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2024-12-20</td>\n",
       "      <td>listed</td>\n",
       "      <td>Zydus Hospira Oncology Private Limited</td>\n",
       "      <td>Zydus Lifesciences Limited</td>\n",
       "      <td>NCT06757283</td>\n",
       "      <td>Evaluation Of Typhoid Conjugate Vaccine (Tcv) ...</td>\n",
       "      <td>PR-24059</td>\n",
       "      <td>Zyvac-Tcv Bangladesh Study</td>\n",
       "      <td>International Centre for Diarrhoeal Disease Re...</td>\n",
       "      <td>International Centre For Diarrhoeal Disease Re...</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>4000</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Very Large</td>\n",
       "      <td>Conjugate vaccine; Immunogenicity; Safety; Typ...</td>\n",
       "      <td>Typhoid Vaccination</td>\n",
       "      <td>BIOLOGICAL</td>\n",
       "      <td>Purified Vi capsular polysaccharide of Salmone...</td>\n",
       "      <td>Purified Vi capsular polysaccharide of Salmone...</td>\n",
       "      <td>Culture-negative control; Culture-positive case</td>\n",
       "      <td>Purified Vi Capsular Polysaccharide Of Salmone...</td>\n",
       "      <td>True</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2025-01-03</td>\n",
       "      <td>2025-01-03</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Dhaka</td>\n",
       "      <td>Bangladesh</td>\n",
       "      <td>lat: 23.7104, lon: 90.40744</td>\n",
       "      <td>International Centre for Diarrhoeal Disease Re...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>ALL</td>\n",
       "      <td>0</td>\n",
       "      <td>15</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>active</td>\n",
       "      <td>2024-12-01</td>\n",
       "      <td>Primary outcome</td>\n",
       "      <td>12 months</td>\n",
       "      <td>Blood culture-confirmed typhoid fever</td>\n",
       "      <td>Secondary outcome; Secondary outcome</td>\n",
       "      <td>12 months; 12 months</td>\n",
       "      <td>Anti-Vi-IgG antibody concentration Blood cultu...</td>\n",
       "      <td>False</td>\n",
       "      <td>Typhoid Vaccination; Typhoid; Typhoid Fever</td>\n",
       "      <td>This Is A Prospective Closed Cohort, Open-Labe...</td>\n",
       "      <td>This Will Be A Phase Iii Effectiveness Study O...</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>Zydus Lifesciences Limited</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.830</td>\n",
       "      <td>0.390</td>\n",
       "      <td>1053.000</td>\n",
       "      <td>0.669</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1481</th>\n",
       "      <td>PFE</td>\n",
       "      <td>2024-12-26</td>\n",
       "      <td>listed</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>NCT06758401</td>\n",
       "      <td>An Open-Label, Randomized, Controlled Phase 3 ...</td>\n",
       "      <td>C5751003</td>\n",
       "      <td>This Is A Study To Learn About How The Combina...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>714</td>\n",
       "      <td>0</td>\n",
       "      <td>False</td>\n",
       "      <td>ESTIMATED</td>\n",
       "      <td>Large</td>\n",
       "      <td>Lung Cancer; Carcinoma, Non-Small-Cell Lung; N...</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>DRUG; DRUG</td>\n",
       "      <td>Sigvotatug Vedotin</td>\n",
       "      <td>Sigvotatug Vedotin; Pembrolizumab</td>\n",
       "      <td>Arm A; Arm A; Arm B</td>\n",
       "      <td>Mmae-Antibody Drug Conjugate Targeting Integri...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2025-01-03</td>\n",
       "      <td>2025-01-03</td>\n",
       "      <td>2025-01-20</td>\n",
       "      <td>2029-02-17</td>\n",
       "      <td>2028-08-24</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>active</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>Overall Survival; Progression Free Survival (P...</td>\n",
       "      <td>Baseline to date of death from any cause (Appr...</td>\n",
       "      <td>Overall survival defined as the duration from ...</td>\n",
       "      <td>Progression Free Survival as assessed by Inves...</td>\n",
       "      <td>From Baseline to date of first progression or ...</td>\n",
       "      <td>Progression Free Survival (PFS) is defined as ...</td>\n",
       "      <td>False</td>\n",
       "      <td>Non-Small Cell Lung Cancer; Carcinoma, Non-Sma...</td>\n",
       "      <td>The Purpose Of The Study Is To Compare How The...</td>\n",
       "      <td>None</td>\n",
       "      <td>SINGLE</td>\n",
       "      <td>RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>False</td>\n",
       "      <td>1489</td>\n",
       "      <td>1489.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>YES</td>\n",
       "      <td>0.920</td>\n",
       "      <td>0.490</td>\n",
       "      <td>1514.000</td>\n",
       "      <td>0.753</td>\n",
       "      <td>INDUSTRY</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1482 rows × 77 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     ticker       date  source                              subsidiary  \\\n",
       "0      AAPL 2018-02-02  listed                             Apple  Inc.   \n",
       "1      AAPL 2018-02-27  listed                             Apple  Inc.   \n",
       "2      AAPL 2018-11-21  listed                             Apple  Inc.   \n",
       "3      AAPL 2018-12-06  listed                             Apple  Inc.   \n",
       "4      AAPL 2019-11-13  listed                             Apple  Inc.   \n",
       "...     ...        ...     ...                                     ...   \n",
       "1477    PFE 2024-12-10  listed                                  Pfizer   \n",
       "1478    PFE 2024-12-11  listed                                  Pfizer   \n",
       "1479    PFE 2024-12-16  listed                                  Pfizer   \n",
       "1480    PFE 2024-12-20  listed  Zydus Hospira Oncology Private Limited   \n",
       "1481    PFE 2024-12-26  listed                                  Pfizer   \n",
       "\n",
       "                         sponsor     trial_id  \\\n",
       "0                     Apple Inc.  NCT03426280   \n",
       "1                     Apple Inc.  NCT03492554   \n",
       "2                     Apple Inc.  NCT03760796   \n",
       "3                     Apple Inc.  NCT03769207   \n",
       "4                     Apple Inc.  NCT04198194   \n",
       "...                          ...          ...   \n",
       "1477                      Pfizer  NCT06733337   \n",
       "1478                      Pfizer  NCT06735742   \n",
       "1479                      Pfizer  NCT06743334   \n",
       "1480  Zydus Lifesciences Limited  NCT06757283   \n",
       "1481                      Pfizer  NCT06758401   \n",
       "\n",
       "                                         official_title sponsor_study_id  \\\n",
       "0     Activity Therapy After Kidney Transplant: A Pi...            44663   \n",
       "1           Electrocardiogram Clinical Validation Study        099-11774   \n",
       "2     The Johns Hopkins Myocardial Infarction, Combi...      IRB00099938   \n",
       "3     Evaluation Of The Use Of Apple Watch Features ...              1.2   \n",
       "4                          Apple Heart & Movement Study      2019P002257   \n",
       "...                                                 ...              ...   \n",
       "1477  Special Investigation Of Talzenna Capsules - S...         C3441050   \n",
       "1478  Talzenna Capsules Special Investigation - Inve...         C3441045   \n",
       "1479  Secondary Databased Post-Marketing Surveillanc...         C4591056   \n",
       "1480  Evaluation Of Typhoid Conjugate Vaccine (Tcv) ...         PR-24059   \n",
       "1481  An Open-Label, Randomized, Controlled Phase 3 ...         C5751003   \n",
       "\n",
       "                                            brief_title  \\\n",
       "0              Activity Therapy After Kidney Transplant   \n",
       "1           Electrocardiogram Clinical Validation Study   \n",
       "2     Myocardial Infarction, Combined-Device, Recove...   \n",
       "3     Evaluation Of The Use Of Apple Watch Features ...   \n",
       "4                          Apple Heart & Movement Study   \n",
       "...                                                 ...   \n",
       "1477  A Study To Learn About The Safety Of Talzenna ...   \n",
       "1478  A Study To Learn About The Safety Of Talzenna ...   \n",
       "1479  Secondary Databased Post-Marketing Surveillanc...   \n",
       "1480                         Zyvac-Tcv Bangladesh Study   \n",
       "1481  This Is A Study To Learn About How The Combina...   \n",
       "\n",
       "                                           lead_sponsor  \\\n",
       "0                                   Stanford University   \n",
       "1                                            Apple Inc.   \n",
       "2                              Johns Hopkins University   \n",
       "3                                            Apple Inc.   \n",
       "4                                            Apple Inc.   \n",
       "...                                                 ...   \n",
       "1477                                             Pfizer   \n",
       "1478                                             Pfizer   \n",
       "1479                                             Pfizer   \n",
       "1480  International Centre for Diarrhoeal Disease Re...   \n",
       "1481                                             Pfizer   \n",
       "\n",
       "                                      lead_sponsor_name sponsor_type  \\\n",
       "0                                   Stanford University        OTHER   \n",
       "1                                            Apple Inc.     INDUSTRY   \n",
       "2                              Johns Hopkins University        OTHER   \n",
       "3                                            Apple Inc.     INDUSTRY   \n",
       "4                                            Apple Inc.     INDUSTRY   \n",
       "...                                                 ...          ...   \n",
       "1477                                             Pfizer     INDUSTRY   \n",
       "1478                                             Pfizer     INDUSTRY   \n",
       "1479                                             Pfizer     INDUSTRY   \n",
       "1480  International Centre For Diarrhoeal Disease Re...        OTHER   \n",
       "1481                                             Pfizer     INDUSTRY   \n",
       "\n",
       "     lead_sponsor_type phase_category      study_type  enrollment_count  \\\n",
       "0                OTHER          other  INTERVENTIONAL                13   \n",
       "1             INDUSTRY          other  INTERVENTIONAL               602   \n",
       "2                OTHER          other  INTERVENTIONAL               200   \n",
       "3             INDUSTRY          other  INTERVENTIONAL                17   \n",
       "4             INDUSTRY  not_specified   OBSERVATIONAL            500000   \n",
       "...                ...            ...             ...               ...   \n",
       "1477          INDUSTRY  not_specified   OBSERVATIONAL               104   \n",
       "1478          INDUSTRY  not_specified   OBSERVATIONAL                37   \n",
       "1479          INDUSTRY  not_specified   OBSERVATIONAL          10890000   \n",
       "1480             OTHER        phase_3  INTERVENTIONAL              4000   \n",
       "1481          INDUSTRY        phase_3  INTERVENTIONAL               714   \n",
       "\n",
       "      number_of_locations healthy_volunteers enrollment_type  \\\n",
       "0                       1              False          ACTUAL   \n",
       "1                       5               True          ACTUAL   \n",
       "2                       4              False          ACTUAL   \n",
       "3                       1               True          ACTUAL   \n",
       "4                       1               None       ESTIMATED   \n",
       "...                   ...                ...             ...   \n",
       "1477                    0              False       ESTIMATED   \n",
       "1478                    0              False       ESTIMATED   \n",
       "1479                    1              False       ESTIMATED   \n",
       "1480                    1               True       ESTIMATED   \n",
       "1481                    0              False       ESTIMATED   \n",
       "\n",
       "     study_size_category                                 condition_keywords  \\\n",
       "0                  Small                                                nan   \n",
       "1                  Large                                                nan   \n",
       "2                 Medium  readmission; cardiovascular disease prevention...   \n",
       "3                  Small                                                nan   \n",
       "4             Very Large                                                nan   \n",
       "...                  ...                                                ...   \n",
       "1477              Medium  BRCA mutation-positive; metastatic castration-...   \n",
       "1478               Small  BRCA mutation-positive and HER2-negative; unre...   \n",
       "1479          Very Large              COVID-19 Vaccines; Safety; SARS-CoV-2   \n",
       "1480          Very Large  Conjugate vaccine; Immunogenicity; Safety; Typ...   \n",
       "1481               Large  Lung Cancer; Carcinoma, Non-Small-Cell Lung; N...   \n",
       "\n",
       "                     primary_condition                   intervention_type  \\\n",
       "0     Kidney Transplant; Complications                              DEVICE   \n",
       "1                  Atrial Fibrillation                       OTHER; DEVICE   \n",
       "2          Acute Myocardial Infarction                              DEVICE   \n",
       "3                  Atrial Fibrillation                              DEVICE   \n",
       "4                           Prevention                     DIAGNOSTIC_TEST   \n",
       "...                                ...                                 ...   \n",
       "1477                   Prostate Cancer                                 nan   \n",
       "1478                     Breast Cancer                                 nan   \n",
       "1479                          Covid-19  BIOLOGICAL; BIOLOGICAL; BIOLOGICAL   \n",
       "1480               Typhoid Vaccination                          BIOLOGICAL   \n",
       "1481        Non-Small Cell Lung Cancer                          DRUG; DRUG   \n",
       "\n",
       "                                   primary_intervention  \\\n",
       "0                                  Apple Watch Series 1   \n",
       "1                                            1-Lead ECG   \n",
       "2                        Corrie Health Digital Platform   \n",
       "3                                        Ambulatory ECG   \n",
       "4                                  Predictors of events   \n",
       "...                                                 ...   \n",
       "1477                                                nan   \n",
       "1478                                                nan   \n",
       "1479                             Tozinameran (BNT162b2)   \n",
       "1480  Purified Vi capsular polysaccharide of Salmone...   \n",
       "1481                                 Sigvotatug Vedotin   \n",
       "\n",
       "                                      intervention_name  \\\n",
       "0                                  Apple Watch Series 1   \n",
       "1                               1-Lead ECG; 12-Lead ECG   \n",
       "2                        Corrie Health Digital Platform   \n",
       "3                                        Ambulatory ECG   \n",
       "4                                  Predictors of events   \n",
       "...                                                 ...   \n",
       "1477                                                nan   \n",
       "1478                                                nan   \n",
       "1479  Tozinameran (BNT162b2); Tozinameran (BNT162b2)...   \n",
       "1480  Purified Vi capsular polysaccharide of Salmone...   \n",
       "1481                  Sigvotatug Vedotin; Pembrolizumab   \n",
       "\n",
       "                          intervention_arm_group_labels  \\\n",
       "0                                           Apple Watch   \n",
       "1     Atrial fibrillation (AF); Normal Sinus Rhythm ...   \n",
       "2                  Corrie Health Digital Platform group   \n",
       "3                                        Ambulatory ECG   \n",
       "4                              Participants with events   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479  All primary series recipients using monovalent...   \n",
       "1480    Culture-negative control; Culture-positive case   \n",
       "1481                                Arm A; Arm A; Arm B   \n",
       "\n",
       "                               intervention_description  \\\n",
       "0     Clinic Pharmacists Will Issue Apple Watches To...   \n",
       "1     All Participants Will Record Three Single-Lead...   \n",
       "2     The Corrie Health Digital Platform Consists Of...   \n",
       "3     Eligible Participants Are Asked To Wear The Am...   \n",
       "4     Apple Heart \\& Movement Study In Apple Researc...   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479  1. 12 Years Or Older\\n\\n   * Primary Series: 2...   \n",
       "1480  Purified Vi Capsular Polysaccharide Of Salmone...   \n",
       "1481  Mmae-Antibody Drug Conjugate Targeting Integri...   \n",
       "\n",
       "     has_data_monitoring_committee responsible_party_investigator_affiliation  \\\n",
       "0                            False                        Stanford University   \n",
       "1                            False                                       None   \n",
       "2                             None                                       None   \n",
       "3                            False                        Stanford University   \n",
       "4                             True               Brigham and Women's Hospital   \n",
       "...                            ...                                        ...   \n",
       "1477                          None                                       None   \n",
       "1478                          None                                       None   \n",
       "1479                         False                                       None   \n",
       "1480                          True                                       None   \n",
       "1481                          None                                       None   \n",
       "\n",
       "                   responsible_party_investigator_title  \\\n",
       "0                          Clinical Assistant Professor   \n",
       "1                                                  None   \n",
       "2                                                  None   \n",
       "3     Assistant Professor of Medicine (Cardiovascula...   \n",
       "4                                Principal Investigator   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                               None   \n",
       "1480                                               None   \n",
       "1481                                               None   \n",
       "\n",
       "     responsible_party_investigator_name first_posted_date  \\\n",
       "0                 Xingxing Shelley Cheng        2018-02-08   \n",
       "1                                   None        2018-04-10   \n",
       "2                                   None        2018-11-30   \n",
       "3                            Marco Perez        2018-12-07   \n",
       "4                        Calum A. Macrae        2019-12-13   \n",
       "...                                  ...               ...   \n",
       "1477                                None        2024-12-13   \n",
       "1478                                None        2024-12-16   \n",
       "1479                                None        2024-12-19   \n",
       "1480                                None        2025-01-03   \n",
       "1481                                None        2025-01-03   \n",
       "\n",
       "     last_update_posted_date start_date study_completion_date  \\\n",
       "0                 2023-06-27 2018-05-01            2020-01-31   \n",
       "1                 2020-12-03 2018-03-12            2018-05-14   \n",
       "2                 2021-07-29 2016-10-01            2019-12-17   \n",
       "3                 2020-10-20 2018-12-08            2019-08-20   \n",
       "4                 2021-07-23        NaT            2024-11-14   \n",
       "...                      ...        ...                   ...   \n",
       "1477              2024-12-13        NaT                   NaT   \n",
       "1478              2024-12-16 2025-01-31            2031-07-25   \n",
       "1479              2024-12-19 2025-05-28            2025-05-28   \n",
       "1480              2025-01-03        NaT                   NaT   \n",
       "1481              2025-01-03 2025-01-20            2029-02-17   \n",
       "\n",
       "     primary_completion_date  \\\n",
       "0                 2020-01-31   \n",
       "1                 2018-05-14   \n",
       "2                 2019-12-17   \n",
       "3                 2019-07-05   \n",
       "4                 2024-11-14   \n",
       "...                      ...   \n",
       "1477                     NaT   \n",
       "1478              2031-07-25   \n",
       "1479              2025-05-28   \n",
       "1480                     NaT   \n",
       "1481              2028-08-24   \n",
       "\n",
       "                                   study_locations_city  \\\n",
       "0                                             Palo Alto   \n",
       "1     Miami; Orlando; The Villages; Overland Park; S...   \n",
       "2                 Baltimore; Baltimore; Boston; Reading   \n",
       "3                                              Stanford   \n",
       "4                                                Boston   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                              Seoul   \n",
       "1480                                              Dhaka   \n",
       "1481                                               None   \n",
       "\n",
       "                                study_locations_country  \\\n",
       "0                                         United States   \n",
       "1     United States; United States; United States; U...   \n",
       "2     United States; United States; United States; U...   \n",
       "3                                         United States   \n",
       "4                                         United States   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                 Korea, Republic of   \n",
       "1480                                         Bangladesh   \n",
       "1481                                               None   \n",
       "\n",
       "                               study_locations_geopoint  \\\n",
       "0                        lat: 37.44188, lon: -122.14302   \n",
       "1     lat: 25.77427, lon: -80.19366; lat: 28.53834, ...   \n",
       "2     lat: 39.29038, lon: -76.61219; lat: 39.29038, ...   \n",
       "3                        lat: 37.42411, lon: -122.16608   \n",
       "4                         lat: 42.35843, lon: -71.05977   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                         lat: 37.566, lon: 126.9784   \n",
       "1480                        lat: 23.7104, lon: 90.40744   \n",
       "1481                                               None   \n",
       "\n",
       "                               study_locations_facility  \\\n",
       "0                          Stanford Hospital and Clinic   \n",
       "1     QPS; BioClinicia- Orlando; BioClinica- The Vil...   \n",
       "2     Johns Hopkins Bayview Medical Center; Johns Ho...   \n",
       "3                                   Stanford University   \n",
       "4                          Brigham and Women's Hospital   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                       Pfizer Korea   \n",
       "1480  International Centre for Diarrhoeal Disease Re...   \n",
       "1481                                               None   \n",
       "\n",
       "                    study_locations_zip  \\\n",
       "0                                 94304   \n",
       "1     33143; 32806; 32162; 66211; 55102   \n",
       "2            21224; 21287; 02114; 19611   \n",
       "3                                 94304   \n",
       "4                                 02115   \n",
       "...                                 ...   \n",
       "1477                               None   \n",
       "1478                               None   \n",
       "1479                               None   \n",
       "1480                               None   \n",
       "1481                               None   \n",
       "\n",
       "                                study_locations_state  \\\n",
       "0                                          California   \n",
       "1        Florida; Florida; Florida; Kansas; Minnesota   \n",
       "2     Maryland; Maryland; Massachusetts; Pennsylvania   \n",
       "3                                          California   \n",
       "4                                       Massachusetts   \n",
       "...                                               ...   \n",
       "1477                                             None   \n",
       "1478                                             None   \n",
       "1479                                             None   \n",
       "1480                                             None   \n",
       "1481                                             None   \n",
       "\n",
       "            standard_age_groups   sex  minimum_age  maximum_age  \\\n",
       "0            ADULT; OLDER_ADULT   ALL           18         <NA>   \n",
       "1            ADULT; OLDER_ADULT   ALL           22         <NA>   \n",
       "2            ADULT; OLDER_ADULT   ALL           18         <NA>   \n",
       "3            ADULT; OLDER_ADULT   ALL           22         <NA>   \n",
       "4            ADULT; OLDER_ADULT   ALL           18         <NA>   \n",
       "...                         ...   ...          ...          ...   \n",
       "1477  CHILD; ADULT; OLDER_ADULT  MALE            0         <NA>   \n",
       "1478  CHILD; ADULT; OLDER_ADULT   ALL            0         <NA>   \n",
       "1479  CHILD; ADULT; OLDER_ADULT   ALL            0         <NA>   \n",
       "1480                      CHILD   ALL            0           15   \n",
       "1481         ADULT; OLDER_ADULT   ALL           18         <NA>   \n",
       "\n",
       "          overall_status status_category status_verified_date  \\\n",
       "0             TERMINATED         stopped           2023-06-01   \n",
       "1              COMPLETED       completed           2020-11-01   \n",
       "2              COMPLETED       completed           2021-07-01   \n",
       "3              COMPLETED       completed           2020-09-01   \n",
       "4                UNKNOWN           other           2021-07-01   \n",
       "...                  ...             ...                  ...   \n",
       "1477  NOT_YET_RECRUITING          active           2024-12-01   \n",
       "1478  NOT_YET_RECRUITING          active           2024-12-01   \n",
       "1479  NOT_YET_RECRUITING          active           2024-12-01   \n",
       "1480  NOT_YET_RECRUITING          active           2024-12-01   \n",
       "1481  NOT_YET_RECRUITING          active           2024-11-01   \n",
       "\n",
       "                              primary_outcomes_measures  \\\n",
       "0     Activity Level (daily caloric consumption); % ...   \n",
       "1     Number of Participants With Software's Rhythm ...   \n",
       "2     Number of Participants Readmitted Within 30-da...   \n",
       "3     Atrial Fibrillation or Atrial Flutter (AF) of ...   \n",
       "4     Number of Participants with Chronic Disease Ev...   \n",
       "...                                                 ...   \n",
       "1477                Incidence of adverse drug reactions   \n",
       "1478                Incidence of adverse drug reactions   \n",
       "1479  Frequency of Adverse Events of Special Interes...   \n",
       "1480                                    Primary outcome   \n",
       "1481  Overall Survival; Progression Free Survival (P...   \n",
       "\n",
       "                            primary_outcomes_timeframes  \\\n",
       "0                        1 year; 1st year of transplant   \n",
       "1                                          1 Day; 1 Day   \n",
       "2                       30-days post hospital discharge   \n",
       "3       During ambulatory ECG Monitoring (up to 8 days)   \n",
       "4     quarterly (every 90 days) through study comple...   \n",
       "...                                                 ...   \n",
       "1477                                     Up to 52 weeks   \n",
       "1478                                     Up to 52 weeks   \n",
       "1479  Up to 270 days after vaccination; Up to 270 da...   \n",
       "1480                                          12 months   \n",
       "1481  Baseline to date of death from any cause (Appr...   \n",
       "\n",
       "                          primary_outcomes_descriptions  \\\n",
       "0                                                  None   \n",
       "1     Specificity of rhythm classification; Sensitiv...   \n",
       "2     Number of participants readmitted within 30-da...   \n",
       "3     Detected on ambulatory ECG patch monitor for a...   \n",
       "4     Change in number of participants with incident...   \n",
       "...                                                 ...   \n",
       "1477  For adverse drug reactions corresponding to my...   \n",
       "1478  For adverse drug reactions corresponding to my...   \n",
       "1479  Measure of Occurrence (Cohort design) The freq...   \n",
       "1480              Blood culture-confirmed typhoid fever   \n",
       "1481  Overall survival defined as the duration from ...   \n",
       "\n",
       "                            secondary_outcomes_measures  \\\n",
       "0                                Weight; Hemoglobin A1c   \n",
       "1     Number of Participants With Software's Ability...   \n",
       "2     Cost-effectiveness as Assessed by a Markov Mod...   \n",
       "3     Arrhythmias Other Than AF; Self-reported Conta...   \n",
       "4                                                  None   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479  Frequency of Severe COVID-19 Outcomes; Inciden...   \n",
       "1480               Secondary outcome; Secondary outcome   \n",
       "1481  Progression Free Survival as assessed by Inves...   \n",
       "\n",
       "                          secondary_outcomes_timeframes  \\\n",
       "0        1st year of transplant; 1st year of transplant   \n",
       "1                                   1 Day; 1 Day; 1 Day   \n",
       "2     30 days post hospital discharge; 3 days post h...   \n",
       "3     During ambulatory ECG Monitoring (up to 8 days...   \n",
       "4                                                  None   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479  Up to 150 days after vaccination; Up to 150 da...   \n",
       "1480                               12 months; 12 months   \n",
       "1481  From Baseline to date of first progression or ...   \n",
       "\n",
       "                        secondary_outcomes_descriptions  has_results  \\\n",
       "0                                                  None        False   \n",
       "1     Number of ECGs that pass a visual overlay; Dif...         True   \n",
       "2     We estimated typical costs associated with rea...         True   \n",
       "3     Detected on an ambulatory ECG patch monitor fo...         True   \n",
       "4                                                  None        False   \n",
       "...                                                 ...          ...   \n",
       "1477                                               None        False   \n",
       "1478                                               None        False   \n",
       "1479  The frequency of severe COVID-19 outcomes incl...        False   \n",
       "1480  Anti-Vi-IgG antibody concentration Blood cultu...        False   \n",
       "1481  Progression Free Survival (PFS) is defined as ...        False   \n",
       "\n",
       "                                             conditions  \\\n",
       "0                      Kidney Transplant; Complications   \n",
       "1                                   Atrial Fibrillation   \n",
       "2     Acute Myocardial Infarction; Coronary Artery D...   \n",
       "3     Atrial Fibrillation; Arrhythmias, Cardiac; Atr...   \n",
       "4                                            Prevention   \n",
       "...                                                 ...   \n",
       "1477                                    Prostate Cancer   \n",
       "1478                                      Breast Cancer   \n",
       "1479                               Covid-19; Sars-Cov-2   \n",
       "1480        Typhoid Vaccination; Typhoid; Typhoid Fever   \n",
       "1481  Non-Small Cell Lung Cancer; Carcinoma, Non-Sma...   \n",
       "\n",
       "                                          brief_summary  \\\n",
       "0     To Combat Post-Transplant Weight Gain, We Seek...   \n",
       "1     The Purpose Of The Study Is To Confirm The Sof...   \n",
       "2     Unplanned Readmissions After Hospitalization F...   \n",
       "3     This Post-Marketing Study Is Conducted To Char...   \n",
       "4     This Study Will Look For Factors That Affect H...   \n",
       "...                                                 ...   \n",
       "1477  The Purpose Of This Study Is To Learn About Th...   \n",
       "1478  The Purpose Of This Study Is To Learn About Th...   \n",
       "1479  This Study Is To Assess The Post-Marketing Saf...   \n",
       "1480  This Is A Prospective Closed Cohort, Open-Labe...   \n",
       "1481  The Purpose Of The Study Is To Compare How The...   \n",
       "\n",
       "                                   detailed_description masking  \\\n",
       "0                                                  None    NONE   \n",
       "1                                                  None    NONE   \n",
       "2                                                  None    NONE   \n",
       "3                                                  None    NONE   \n",
       "4                                                  None    None   \n",
       "...                                                 ...     ...   \n",
       "1477                                               None    None   \n",
       "1478                                               None    None   \n",
       "1479  This Study Is A Retrospective, Non-Interventio...    None   \n",
       "1480  This Will Be A Phase Iii Effectiveness Study O...    NONE   \n",
       "1481                                               None  SINGLE   \n",
       "\n",
       "          allocation intervention_model primary_purpose  has_expanded_access  \\\n",
       "0     NON_RANDOMIZED           PARALLEL       TREATMENT                False   \n",
       "1     NON_RANDOMIZED           PARALLEL   BASIC_SCIENCE                False   \n",
       "2                 NA       SINGLE_GROUP      PREVENTION                False   \n",
       "3                 NA       SINGLE_GROUP           OTHER                False   \n",
       "4               None               None            None                False   \n",
       "...              ...                ...             ...                  ...   \n",
       "1477            None               None            None                False   \n",
       "1478            None               None            None                False   \n",
       "1479            None               None            None                False   \n",
       "1480  NON_RANDOMIZED       SINGLE_GROUP      PREVENTION                False   \n",
       "1481      RANDOMIZED           PARALLEL       TREATMENT                False   \n",
       "\n",
       "      study_duration_days  trial_duration  \\\n",
       "0                     640         640.000   \n",
       "1                      63          63.000   \n",
       "2                    1172        1172.000   \n",
       "3                     255         255.000   \n",
       "4                    <NA>             NaN   \n",
       "...                   ...             ...   \n",
       "1477                 <NA>             NaN   \n",
       "1478                 2366        2366.000   \n",
       "1479                    0           0.000   \n",
       "1480                 <NA>             NaN   \n",
       "1481                 1489        1489.000   \n",
       "\n",
       "                                        references_type  \\\n",
       "0                                                  None   \n",
       "1                                                  None   \n",
       "2     BACKGROUND; BACKGROUND; BACKGROUND; RESULT; RE...   \n",
       "3                                                  None   \n",
       "4                                                  None   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                               None   \n",
       "1480                                               None   \n",
       "1481                                               None   \n",
       "\n",
       "                                    references_citation  \\\n",
       "0                                                  None   \n",
       "1                                                  None   \n",
       "2     Spaulding EM, Marvel FA, Lee MA, Yang WE, Demo...   \n",
       "3                                                  None   \n",
       "4                                                  None   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                               None   \n",
       "1480                                               None   \n",
       "1481                                               None   \n",
       "\n",
       "                                        references_pmid  \\\n",
       "0                                                  None   \n",
       "1                                                  None   \n",
       "2     31043065; 31094337; 31758761; 33999374; 329642...   \n",
       "3                                                  None   \n",
       "4                                                  None   \n",
       "...                                                 ...   \n",
       "1477                                               None   \n",
       "1478                                               None   \n",
       "1479                                               None   \n",
       "1480                                               None   \n",
       "1481                                               None   \n",
       "\n",
       "              collaborators_name collaborators_class ipd_sharing  \\\n",
       "0                     Apple Inc.            INDUSTRY          NO   \n",
       "1                  Iqvia Pty Ltd            INDUSTRY          NO   \n",
       "2            Apple Inc.; iHealth     INDUSTRY; OTHER          NO   \n",
       "3                           None                None          NO   \n",
       "4     American Heart Association               OTHER          NO   \n",
       "...                          ...                 ...         ...   \n",
       "1477                        None                None          NO   \n",
       "1478                        None                None          NO   \n",
       "1479                        None                None          NO   \n",
       "1480  Zydus Lifesciences Limited            INDUSTRY          NO   \n",
       "1481                        None                None         YES   \n",
       "\n",
       "      success_prediction  economic_effect  duration_prediction  \\\n",
       "0                  0.110            0.050              640.000   \n",
       "1                  0.930            0.660               63.000   \n",
       "2                  0.950            0.560             1172.000   \n",
       "3                  0.860            0.530              255.000   \n",
       "4                  0.280            0.050              618.000   \n",
       "...                  ...              ...                  ...   \n",
       "1477               0.290            0.060              733.000   \n",
       "1478               0.260            0.040             2417.000   \n",
       "1479               0.280            0.050              163.000   \n",
       "1480               0.830            0.390             1053.000   \n",
       "1481               0.920            0.490             1514.000   \n",
       "\n",
       "      success_composite     class  \n",
       "0                 0.069  INDUSTRY  \n",
       "1                 0.774  INDUSTRY  \n",
       "2                 0.735  INDUSTRY  \n",
       "3                 0.683  INDUSTRY  \n",
       "4                 0.169  INDUSTRY  \n",
       "...                 ...       ...  \n",
       "1477              0.177  INDUSTRY  \n",
       "1478              0.139  INDUSTRY  \n",
       "1479              0.177  INDUSTRY  \n",
       "1480              0.669  INDUSTRY  \n",
       "1481              0.753  INDUSTRY  \n",
       "\n",
       "[1482 rows x 77 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_apps"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_clinical = sov.data(\"trials/predict\", full_history=True) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_clinical[\"links\"] = \"https://clinicaltrials.gov/study/\" + df_clinical[\"trial_id\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>ticker</th>\n",
       "      <th>trial_id</th>\n",
       "      <th>lead_sponsor_name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>phase_category</th>\n",
       "      <th>success_prediction</th>\n",
       "      <th>economic_effect</th>\n",
       "      <th>duration_prediction</th>\n",
       "      <th>success_composite</th>\n",
       "      <th>links</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2010-08-12</td>\n",
       "      <td>A</td>\n",
       "      <td>NCT01181479</td>\n",
       "      <td>Agile Therapeutics</td>\n",
       "      <td>Open-Label, Randomized, Parallel Group, Study ...</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.970</td>\n",
       "      <td>0.630</td>\n",
       "      <td>2882.000</td>\n",
       "      <td>0.841</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT01181479</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>A</td>\n",
       "      <td>NCT01236768</td>\n",
       "      <td>Agile Therapeutics</td>\n",
       "      <td>An Open-Label, Randomized, Phase 3 Study Of Th...</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.670</td>\n",
       "      <td>2506.000</td>\n",
       "      <td>0.846</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT01236768</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2010-11-16</td>\n",
       "      <td>A</td>\n",
       "      <td>NCT01243580</td>\n",
       "      <td>Agile Therapeutics</td>\n",
       "      <td>An Open-Label Study To Evaluate Pharmacokineti...</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>0.960</td>\n",
       "      <td>0.630</td>\n",
       "      <td>2590.000</td>\n",
       "      <td>0.793</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT01243580</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2010-11-29</td>\n",
       "      <td>A</td>\n",
       "      <td>NCT01250210</td>\n",
       "      <td>Agile Therapeutics</td>\n",
       "      <td>Evaluation Of Pharmacodynamic Effects On Ovula...</td>\n",
       "      <td>phase_2</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.700</td>\n",
       "      <td>1084.000</td>\n",
       "      <td>0.850</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT01250210</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2011-06-13</td>\n",
       "      <td>A</td>\n",
       "      <td>NCT01375946</td>\n",
       "      <td>Agile Therapeutics</td>\n",
       "      <td>A Pharmacokinetic And Wearability Study Of The...</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>0.940</td>\n",
       "      <td>0.630</td>\n",
       "      <td>2383.000</td>\n",
       "      <td>0.783</td>\n",
       "      <td>https://clinicaltrials.gov/study/NCT01375946</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        date ticker     trial_id   lead_sponsor_name  \\\n",
       "0 2010-08-12      A  NCT01181479  Agile Therapeutics   \n",
       "1 2010-11-05      A  NCT01236768  Agile Therapeutics   \n",
       "2 2010-11-16      A  NCT01243580  Agile Therapeutics   \n",
       "3 2010-11-29      A  NCT01250210  Agile Therapeutics   \n",
       "4 2011-06-13      A  NCT01375946  Agile Therapeutics   \n",
       "\n",
       "                                      official_title phase_category  \\\n",
       "0  Open-Label, Randomized, Parallel Group, Study ...        phase_3   \n",
       "1  An Open-Label, Randomized, Phase 3 Study Of Th...        phase_3   \n",
       "2  An Open-Label Study To Evaluate Pharmacokineti...        phase_1   \n",
       "3  Evaluation Of Pharmacodynamic Effects On Ovula...        phase_2   \n",
       "4  A Pharmacokinetic And Wearability Study Of The...        phase_1   \n",
       "\n",
       "   success_prediction  economic_effect  duration_prediction  \\\n",
       "0               0.970            0.630             2882.000   \n",
       "1               0.950            0.670             2506.000   \n",
       "2               0.960            0.630             2590.000   \n",
       "3               0.950            0.700             1084.000   \n",
       "4               0.940            0.630             2383.000   \n",
       "\n",
       "   success_composite                                         links  \n",
       "0              0.841  https://clinicaltrials.gov/study/NCT01181479  \n",
       "1              0.846  https://clinicaltrials.gov/study/NCT01236768  \n",
       "2              0.793  https://clinicaltrials.gov/study/NCT01243580  \n",
       "3              0.850  https://clinicaltrials.gov/study/NCT01250210  \n",
       "4              0.783  https://clinicaltrials.gov/study/NCT01375946  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_clinical.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Trial Information"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_describe = sov.data(\"trials/describe\", full_history=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ticker</th>\n",
       "      <th>date</th>\n",
       "      <th>trial_id</th>\n",
       "      <th>official_title</th>\n",
       "      <th>sponsor_study_id</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>lead_sponsor_name</th>\n",
       "      <th>sponsor_type</th>\n",
       "      <th>phase_category</th>\n",
       "      <th>study_type</th>\n",
       "      <th>enrollment_count</th>\n",
       "      <th>number_of_locations</th>\n",
       "      <th>healthy_volunteers</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>study_size_category</th>\n",
       "      <th>condition_keywords</th>\n",
       "      <th>primary_condition</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>primary_intervention</th>\n",
       "      <th>intervention_name</th>\n",
       "      <th>intervention_arm_group_labels</th>\n",
       "      <th>intervention_description</th>\n",
       "      <th>has_data_monitoring_committee</th>\n",
       "      <th>responsible_party_investigator_affiliation</th>\n",
       "      <th>responsible_party_investigator_title</th>\n",
       "      <th>responsible_party_investigator_name</th>\n",
       "      <th>first_posted_date</th>\n",
       "      <th>last_update_posted_date</th>\n",
       "      <th>start_date</th>\n",
       "      <th>study_completion_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>study_locations_city</th>\n",
       "      <th>study_locations_country</th>\n",
       "      <th>study_locations_geopoint</th>\n",
       "      <th>study_locations_facility</th>\n",
       "      <th>study_locations_zip</th>\n",
       "      <th>study_locations_state</th>\n",
       "      <th>standard_age_groups</th>\n",
       "      <th>sex</th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>maximum_age</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>status_category</th>\n",
       "      <th>status_verified_date</th>\n",
       "      <th>primary_outcomes_measures</th>\n",
       "      <th>primary_outcomes_timeframes</th>\n",
       "      <th>primary_outcomes_descriptions</th>\n",
       "      <th>secondary_outcomes_measures</th>\n",
       "      <th>secondary_outcomes_timeframes</th>\n",
       "      <th>secondary_outcomes_descriptions</th>\n",
       "      <th>has_results</th>\n",
       "      <th>conditions</th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>masking</th>\n",
       "      <th>allocation</th>\n",
       "      <th>intervention_model</th>\n",
       "      <th>primary_purpose</th>\n",
       "      <th>has_expanded_access</th>\n",
       "      <th>study_duration_days</th>\n",
       "      <th>trial_duration</th>\n",
       "      <th>references_type</th>\n",
       "      <th>references_citation</th>\n",
       "      <th>references_pmid</th>\n",
       "      <th>collaborators_name</th>\n",
       "      <th>collaborators_class</th>\n",
       "      <th>ipd_sharing</th>\n",
       "      <th>success_prediction</th>\n",
       "      <th>economic_effect</th>\n",
       "      <th>duration_prediction</th>\n",
       "      <th>success_composite</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>513998</th>\n",
       "      <td>ZYXI</td>\n",
       "      <td>2021-08-06</td>\n",
       "      <td>NCT05012462</td>\n",
       "      <td>Clinical Evaluation Of The Cm-1500 During Aphe...</td>\n",
       "      <td>ZMS-1500-2021-Apheresis</td>\n",
       "      <td>Clinical Evaluation Of The Cm-1500 During Aphe...</td>\n",
       "      <td>Zynex Monitoring Solutions</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>75</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>CM-1500</td>\n",
       "      <td>CM-1500</td>\n",
       "      <td>None</td>\n",
       "      <td>The Cm-1500 Is A U.S. Fda Cleared Non-Invasive...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2021-08-19</td>\n",
       "      <td>2022-12-21</td>\n",
       "      <td>2021-09-20</td>\n",
       "      <td>2022-12-20</td>\n",
       "      <td>2022-12-20</td>\n",
       "      <td>Denver</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 39.73915, lon: -104.9847</td>\n",
       "      <td>Vitalant Blood Donation</td>\n",
       "      <td>80230</td>\n",
       "      <td>Colorado</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2022-12-01</td>\n",
       "      <td>Characterize changes in the Relative Index dur...</td>\n",
       "      <td>1-6 hours</td>\n",
       "      <td>The primary objective of the study is to chara...</td>\n",
       "      <td>Characterize changes in blood pressure relativ...</td>\n",
       "      <td>1-6 hours; 1-6 hours; 1-6 hours; 1-6 hours</td>\n",
       "      <td>Characterize changes in blood pressure that oc...</td>\n",
       "      <td>False</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>The Study Is A Prospective, Single-Arm, Non-Ra...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>456</td>\n",
       "      <td>456.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.270</td>\n",
       "      <td>0.080</td>\n",
       "      <td>456.000</td>\n",
       "      <td>0.211</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>513999</th>\n",
       "      <td>ZYXI</td>\n",
       "      <td>2021-11-08</td>\n",
       "      <td>NCT05125848</td>\n",
       "      <td>Clinical Evaluation Of The Cm-1500 During Hemo...</td>\n",
       "      <td>ZMS-1500-2021-Dialysis</td>\n",
       "      <td>Clinical Evaluation Of The Cm-1500 During Hemo...</td>\n",
       "      <td>Zynex Monitoring Solutions</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>15</td>\n",
       "      <td>1</td>\n",
       "      <td>False</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>CM-1500</td>\n",
       "      <td>CM-1500</td>\n",
       "      <td>Hemodialysis Single Group Assignment</td>\n",
       "      <td>The Cm-1500 Is A U.S. Fda Cleared Non-Invasive...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2021-11-18</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Minneapolis</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 44.97997, lon: -93.26384</td>\n",
       "      <td>DaVita Clinical Research</td>\n",
       "      <td>55404</td>\n",
       "      <td>Minnesota</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-04-01</td>\n",
       "      <td>Average Relative Index Value Following a Hemod...</td>\n",
       "      <td>Duration of post-hemodialysis recovery period ...</td>\n",
       "      <td>The primary objective is to characterize the a...</td>\n",
       "      <td>Mean Intrasubject Variability (Standard Deviat...</td>\n",
       "      <td>Duration of standard dialysis procedure (Range...</td>\n",
       "      <td>The secondary objective is to characterize int...</td>\n",
       "      <td>True</td>\n",
       "      <td>Fluid Loss; Dialysis</td>\n",
       "      <td>The Study Is A Prospective, Single-Arm, Non-Ra...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>0.560</td>\n",
       "      <td>0.290</td>\n",
       "      <td>905.000</td>\n",
       "      <td>0.443</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>514000</th>\n",
       "      <td>ZYXI</td>\n",
       "      <td>2022-07-14</td>\n",
       "      <td>NCT05463198</td>\n",
       "      <td>Evaluation Of Physiological Variables And Dete...</td>\n",
       "      <td>ZMS-1600-Blood Loss Detection</td>\n",
       "      <td>Evaluation Of Physiological Variables And Dete...</td>\n",
       "      <td>Zynex Monitoring Solutions</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>351</td>\n",
       "      <td>4</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Medium</td>\n",
       "      <td>nan</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>CM-1600</td>\n",
       "      <td>CM-1600</td>\n",
       "      <td>Blood Loss</td>\n",
       "      <td>Subjects Undergoing Blood Donation Will Be Con...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2022-07-18</td>\n",
       "      <td>2024-08-13</td>\n",
       "      <td>2022-09-14</td>\n",
       "      <td>2023-05-26</td>\n",
       "      <td>2023-04-27</td>\n",
       "      <td>Denver; Bradenton; Columbus; Chattanooga</td>\n",
       "      <td>United States; United States; United States; U...</td>\n",
       "      <td>lat: 39.73915, lon: -104.9847; lat: 27.49893, ...</td>\n",
       "      <td>Vitalant Research Institute; SunCoast Blood Ce...</td>\n",
       "      <td>80230; 34211; 31904; 37403</td>\n",
       "      <td>Colorado; Florida; Georgia; Tennessee</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-07-01</td>\n",
       "      <td>Change in the Relative Index (RI) After Minor ...</td>\n",
       "      <td>Recovery period following donation (10 minutes)</td>\n",
       "      <td>The objective of this study is to determine if...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>True</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>The Study Is A Prospective, Non-Randomized, No...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>254</td>\n",
       "      <td>254.000</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.910</td>\n",
       "      <td>0.520</td>\n",
       "      <td>254.000</td>\n",
       "      <td>0.732</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>514001</th>\n",
       "      <td>ZYXI</td>\n",
       "      <td>2023-02-13</td>\n",
       "      <td>NCT05740644</td>\n",
       "      <td>Clinical Evaluation Of The Zynex Monitoring Sy...</td>\n",
       "      <td>PR 2022-516</td>\n",
       "      <td>Clinical Evaluation Of The Zynex Monitoring Sy...</td>\n",
       "      <td>Zynex Monitoring Solutions</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>20</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Small</td>\n",
       "      <td>nan</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>DEVICE</td>\n",
       "      <td>CM-1600</td>\n",
       "      <td>CM-1600</td>\n",
       "      <td>Blood Loss and Saline Infusion</td>\n",
       "      <td>Healthy Subjects Undergoing A Manual Blood Los...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2023-02-23</td>\n",
       "      <td>2024-07-16</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Louisville</td>\n",
       "      <td>United States</td>\n",
       "      <td>lat: 39.97776, lon: -105.13193</td>\n",
       "      <td>Clinimark</td>\n",
       "      <td>80027</td>\n",
       "      <td>Colorado</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-06-01</td>\n",
       "      <td>CM-1600 Ability to Detect Minor Blood Loss; CM...</td>\n",
       "      <td>Duration of Recovery Period following blood dr...</td>\n",
       "      <td>The objective of this study is to determine if...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>True</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>This Is A Prospective, Single-Arm, Non-Randomi...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NA</td>\n",
       "      <td>SINGLE_GROUP</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.460</td>\n",
       "      <td>0.180</td>\n",
       "      <td>519.000</td>\n",
       "      <td>0.353</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>514002</th>\n",
       "      <td>ZYXI</td>\n",
       "      <td>2023-07-26</td>\n",
       "      <td>NCT05980013</td>\n",
       "      <td>Evaluation Of Physiological Variables And Dete...</td>\n",
       "      <td>ZMS-1500-Pa2023</td>\n",
       "      <td>Evaluation Of Physiological Variables And Dete...</td>\n",
       "      <td>Zynex Monitoring Solutions</td>\n",
       "      <td>INDUSTRY</td>\n",
       "      <td>other</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>120</td>\n",
       "      <td>2</td>\n",
       "      <td>True</td>\n",
       "      <td>ACTUAL</td>\n",
       "      <td>Medium</td>\n",
       "      <td>nan</td>\n",
       "      <td>Fluid Loss</td>\n",
       "      <td>DEVICE; DEVICE</td>\n",
       "      <td>Whole blood donation supine</td>\n",
       "      <td>Whole blood donation supine; Whole blood donat...</td>\n",
       "      <td>Supine Donation Position; Reclined Donation Po...</td>\n",
       "      <td>Subjects Will Undergo A 1-Unit Whole Blood Don...</td>\n",
       "      <td>False</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>2023-08-07</td>\n",
       "      <td>2024-05-16</td>\n",
       "      <td>2023-08-28</td>\n",
       "      <td>NaT</td>\n",
       "      <td>2024-04-10</td>\n",
       "      <td>Denver; Bradenton</td>\n",
       "      <td>United States; United States</td>\n",
       "      <td>lat: 39.73915, lon: -104.9847; lat: 27.49893, ...</td>\n",
       "      <td>Vitalant Research Institute; SunCoast Blood Ce...</td>\n",
       "      <td>80230; 34211</td>\n",
       "      <td>Colorado; Florida</td>\n",
       "      <td>ADULT; OLDER_ADULT</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>completed</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>Impact of subject positioning on percent chang...</td>\n",
       "      <td>At completion of blood draw</td>\n",
       "      <td>Percent change in heart rate, forearm skin tem...</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>False</td>\n",
       "      <td>Fluid Loss; Blood Loss</td>\n",
       "      <td>The Study Is A Prospective, Non-Randomized, No...</td>\n",
       "      <td>None</td>\n",
       "      <td>NONE</td>\n",
       "      <td>NON_RANDOMIZED</td>\n",
       "      <td>PARALLEL</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>False</td>\n",
       "      <td>&lt;NA&gt;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>None</td>\n",
       "      <td>NO</td>\n",
       "      <td>0.260</td>\n",
       "      <td>0.050</td>\n",
       "      <td>226.000</td>\n",
       "      <td>0.199</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       ticker       date     trial_id  \\\n",
       "513998   ZYXI 2021-08-06  NCT05012462   \n",
       "513999   ZYXI 2021-11-08  NCT05125848   \n",
       "514000   ZYXI 2022-07-14  NCT05463198   \n",
       "514001   ZYXI 2023-02-13  NCT05740644   \n",
       "514002   ZYXI 2023-07-26  NCT05980013   \n",
       "\n",
       "                                           official_title  \\\n",
       "513998  Clinical Evaluation Of The Cm-1500 During Aphe...   \n",
       "513999  Clinical Evaluation Of The Cm-1500 During Hemo...   \n",
       "514000  Evaluation Of Physiological Variables And Dete...   \n",
       "514001  Clinical Evaluation Of The Zynex Monitoring Sy...   \n",
       "514002  Evaluation Of Physiological Variables And Dete...   \n",
       "\n",
       "                     sponsor_study_id  \\\n",
       "513998        ZMS-1500-2021-Apheresis   \n",
       "513999         ZMS-1500-2021-Dialysis   \n",
       "514000  ZMS-1600-Blood Loss Detection   \n",
       "514001                    PR 2022-516   \n",
       "514002                ZMS-1500-Pa2023   \n",
       "\n",
       "                                              brief_title  \\\n",
       "513998  Clinical Evaluation Of The Cm-1500 During Aphe...   \n",
       "513999  Clinical Evaluation Of The Cm-1500 During Hemo...   \n",
       "514000  Evaluation Of Physiological Variables And Dete...   \n",
       "514001  Clinical Evaluation Of The Zynex Monitoring Sy...   \n",
       "514002  Evaluation Of Physiological Variables And Dete...   \n",
       "\n",
       "                 lead_sponsor_name sponsor_type phase_category  \\\n",
       "513998  Zynex Monitoring Solutions     INDUSTRY          other   \n",
       "513999  Zynex Monitoring Solutions     INDUSTRY          other   \n",
       "514000  Zynex Monitoring Solutions     INDUSTRY          other   \n",
       "514001  Zynex Monitoring Solutions     INDUSTRY          other   \n",
       "514002  Zynex Monitoring Solutions     INDUSTRY          other   \n",
       "\n",
       "            study_type  enrollment_count  number_of_locations  \\\n",
       "513998  INTERVENTIONAL                75                    1   \n",
       "513999  INTERVENTIONAL                15                    1   \n",
       "514000  INTERVENTIONAL               351                    4   \n",
       "514001  INTERVENTIONAL                20                    1   \n",
       "514002  INTERVENTIONAL               120                    2   \n",
       "\n",
       "       healthy_volunteers enrollment_type study_size_category  \\\n",
       "513998               True          ACTUAL               Small   \n",
       "513999              False          ACTUAL               Small   \n",
       "514000               True          ACTUAL              Medium   \n",
       "514001               True          ACTUAL               Small   \n",
       "514002               True          ACTUAL              Medium   \n",
       "\n",
       "       condition_keywords primary_condition intervention_type  \\\n",
       "513998                nan        Fluid Loss            DEVICE   \n",
       "513999                nan        Fluid Loss            DEVICE   \n",
       "514000                nan        Fluid Loss            DEVICE   \n",
       "514001                nan        Fluid Loss            DEVICE   \n",
       "514002                nan        Fluid Loss    DEVICE; DEVICE   \n",
       "\n",
       "               primary_intervention  \\\n",
       "513998                      CM-1500   \n",
       "513999                      CM-1500   \n",
       "514000                      CM-1600   \n",
       "514001                      CM-1600   \n",
       "514002  Whole blood donation supine   \n",
       "\n",
       "                                        intervention_name  \\\n",
       "513998                                            CM-1500   \n",
       "513999                                            CM-1500   \n",
       "514000                                            CM-1600   \n",
       "514001                                            CM-1600   \n",
       "514002  Whole blood donation supine; Whole blood donat...   \n",
       "\n",
       "                            intervention_arm_group_labels  \\\n",
       "513998                                               None   \n",
       "513999               Hemodialysis Single Group Assignment   \n",
       "514000                                         Blood Loss   \n",
       "514001                     Blood Loss and Saline Infusion   \n",
       "514002  Supine Donation Position; Reclined Donation Po...   \n",
       "\n",
       "                                 intervention_description  \\\n",
       "513998  The Cm-1500 Is A U.S. Fda Cleared Non-Invasive...   \n",
       "513999  The Cm-1500 Is A U.S. Fda Cleared Non-Invasive...   \n",
       "514000  Subjects Undergoing Blood Donation Will Be Con...   \n",
       "514001  Healthy Subjects Undergoing A Manual Blood Los...   \n",
       "514002  Subjects Will Undergo A 1-Unit Whole Blood Don...   \n",
       "\n",
       "       has_data_monitoring_committee  \\\n",
       "513998                         False   \n",
       "513999                         False   \n",
       "514000                         False   \n",
       "514001                         False   \n",
       "514002                         False   \n",
       "\n",
       "       responsible_party_investigator_affiliation  \\\n",
       "513998                                       None   \n",
       "513999                                       None   \n",
       "514000                                       None   \n",
       "514001                                       None   \n",
       "514002                                       None   \n",
       "\n",
       "       responsible_party_investigator_title  \\\n",
       "513998                                 None   \n",
       "513999                                 None   \n",
       "514000                                 None   \n",
       "514001                                 None   \n",
       "514002                                 None   \n",
       "\n",
       "       responsible_party_investigator_name first_posted_date  \\\n",
       "513998                                None        2021-08-19   \n",
       "513999                                None        2021-11-18   \n",
       "514000                                None        2022-07-18   \n",
       "514001                                None        2023-02-23   \n",
       "514002                                None        2023-08-07   \n",
       "\n",
       "       last_update_posted_date start_date study_completion_date  \\\n",
       "513998              2022-12-21 2021-09-20            2022-12-20   \n",
       "513999              2024-05-01        NaT                   NaT   \n",
       "514000              2024-08-13 2022-09-14            2023-05-26   \n",
       "514001              2024-07-16        NaT                   NaT   \n",
       "514002              2024-05-16 2023-08-28                   NaT   \n",
       "\n",
       "       primary_completion_date                      study_locations_city  \\\n",
       "513998              2022-12-20                                    Denver   \n",
       "513999                     NaT                               Minneapolis   \n",
       "514000              2023-04-27  Denver; Bradenton; Columbus; Chattanooga   \n",
       "514001                     NaT                                Louisville   \n",
       "514002              2024-04-10                         Denver; Bradenton   \n",
       "\n",
       "                                  study_locations_country  \\\n",
       "513998                                      United States   \n",
       "513999                                      United States   \n",
       "514000  United States; United States; United States; U...   \n",
       "514001                                      United States   \n",
       "514002                       United States; United States   \n",
       "\n",
       "                                 study_locations_geopoint  \\\n",
       "513998                      lat: 39.73915, lon: -104.9847   \n",
       "513999                      lat: 44.97997, lon: -93.26384   \n",
       "514000  lat: 39.73915, lon: -104.9847; lat: 27.49893, ...   \n",
       "514001                     lat: 39.97776, lon: -105.13193   \n",
       "514002  lat: 39.73915, lon: -104.9847; lat: 27.49893, ...   \n",
       "\n",
       "                                 study_locations_facility  \\\n",
       "513998                            Vitalant Blood Donation   \n",
       "513999                           DaVita Clinical Research   \n",
       "514000  Vitalant Research Institute; SunCoast Blood Ce...   \n",
       "514001                                          Clinimark   \n",
       "514002  Vitalant Research Institute; SunCoast Blood Ce...   \n",
       "\n",
       "               study_locations_zip                  study_locations_state  \\\n",
       "513998                       80230                               Colorado   \n",
       "513999                       55404                              Minnesota   \n",
       "514000  80230; 34211; 31904; 37403  Colorado; Florida; Georgia; Tennessee   \n",
       "514001                       80027                               Colorado   \n",
       "514002                80230; 34211                      Colorado; Florida   \n",
       "\n",
       "       standard_age_groups  sex  minimum_age  maximum_age overall_status  \\\n",
       "513998  ADULT; OLDER_ADULT  ALL           18         <NA>      COMPLETED   \n",
       "513999  ADULT; OLDER_ADULT  ALL           18         <NA>      COMPLETED   \n",
       "514000  ADULT; OLDER_ADULT  ALL           18         <NA>      COMPLETED   \n",
       "514001  ADULT; OLDER_ADULT  ALL           18         <NA>      COMPLETED   \n",
       "514002  ADULT; OLDER_ADULT  ALL           18         <NA>      COMPLETED   \n",
       "\n",
       "       status_category status_verified_date  \\\n",
       "513998       completed           2022-12-01   \n",
       "513999       completed           2024-04-01   \n",
       "514000       completed           2024-07-01   \n",
       "514001       completed           2024-06-01   \n",
       "514002       completed           2024-05-01   \n",
       "\n",
       "                                primary_outcomes_measures  \\\n",
       "513998  Characterize changes in the Relative Index dur...   \n",
       "513999  Average Relative Index Value Following a Hemod...   \n",
       "514000  Change in the Relative Index (RI) After Minor ...   \n",
       "514001  CM-1600 Ability to Detect Minor Blood Loss; CM...   \n",
       "514002  Impact of subject positioning on percent chang...   \n",
       "\n",
       "                              primary_outcomes_timeframes  \\\n",
       "513998                                          1-6 hours   \n",
       "513999  Duration of post-hemodialysis recovery period ...   \n",
       "514000    Recovery period following donation (10 minutes)   \n",
       "514001  Duration of Recovery Period following blood dr...   \n",
       "514002                        At completion of blood draw   \n",
       "\n",
       "                            primary_outcomes_descriptions  \\\n",
       "513998  The primary objective of the study is to chara...   \n",
       "513999  The primary objective is to characterize the a...   \n",
       "514000  The objective of this study is to determine if...   \n",
       "514001  The objective of this study is to determine if...   \n",
       "514002  Percent change in heart rate, forearm skin tem...   \n",
       "\n",
       "                              secondary_outcomes_measures  \\\n",
       "513998  Characterize changes in blood pressure relativ...   \n",
       "513999  Mean Intrasubject Variability (Standard Deviat...   \n",
       "514000                                               None   \n",
       "514001                                               None   \n",
       "514002                                               None   \n",
       "\n",
       "                            secondary_outcomes_timeframes  \\\n",
       "513998         1-6 hours; 1-6 hours; 1-6 hours; 1-6 hours   \n",
       "513999  Duration of standard dialysis procedure (Range...   \n",
       "514000                                               None   \n",
       "514001                                               None   \n",
       "514002                                               None   \n",
       "\n",
       "                          secondary_outcomes_descriptions  has_results  \\\n",
       "513998  Characterize changes in blood pressure that oc...        False   \n",
       "513999  The secondary objective is to characterize int...         True   \n",
       "514000                                               None         True   \n",
       "514001                                               None         True   \n",
       "514002                                               None        False   \n",
       "\n",
       "                    conditions  \\\n",
       "513998              Fluid Loss   \n",
       "513999    Fluid Loss; Dialysis   \n",
       "514000              Fluid Loss   \n",
       "514001              Fluid Loss   \n",
       "514002  Fluid Loss; Blood Loss   \n",
       "\n",
       "                                            brief_summary  \\\n",
       "513998  The Study Is A Prospective, Single-Arm, Non-Ra...   \n",
       "513999  The Study Is A Prospective, Single-Arm, Non-Ra...   \n",
       "514000  The Study Is A Prospective, Non-Randomized, No...   \n",
       "514001  This Is A Prospective, Single-Arm, Non-Randomi...   \n",
       "514002  The Study Is A Prospective, Non-Randomized, No...   \n",
       "\n",
       "       detailed_description masking      allocation intervention_model  \\\n",
       "513998                 None    NONE              NA       SINGLE_GROUP   \n",
       "513999                 None    NONE              NA       SINGLE_GROUP   \n",
       "514000                 None    NONE              NA       SINGLE_GROUP   \n",
       "514001                 None    NONE              NA       SINGLE_GROUP   \n",
       "514002                 None    NONE  NON_RANDOMIZED           PARALLEL   \n",
       "\n",
       "       primary_purpose  has_expanded_access  study_duration_days  \\\n",
       "513998      DIAGNOSTIC                False                  456   \n",
       "513999      DIAGNOSTIC                False                 <NA>   \n",
       "514000      DIAGNOSTIC                False                  254   \n",
       "514001      DIAGNOSTIC                False                 <NA>   \n",
       "514002      DIAGNOSTIC                False                 <NA>   \n",
       "\n",
       "        trial_duration references_type references_citation references_pmid  \\\n",
       "513998         456.000            None                None            None   \n",
       "513999             NaN            None                None            None   \n",
       "514000         254.000            None                None            None   \n",
       "514001             NaN            None                None            None   \n",
       "514002             NaN            None                None            None   \n",
       "\n",
       "       collaborators_name collaborators_class ipd_sharing  success_prediction  \\\n",
       "513998               None                None          NO               0.270   \n",
       "513999               None                None        None               0.560   \n",
       "514000               None                None          NO               0.910   \n",
       "514001               None                None          NO               0.460   \n",
       "514002               None                None          NO               0.260   \n",
       "\n",
       "        economic_effect  duration_prediction  success_composite  \n",
       "513998            0.080              456.000              0.211  \n",
       "513999            0.290              905.000              0.443  \n",
       "514000            0.520              254.000              0.732  \n",
       "514001            0.180              519.000              0.353  \n",
       "514002            0.050              226.000              0.199  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_describe.tail()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Specific Tickers Select"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_pfizer = sov.data(\"trials/predict\", tickers=[\"PFE\"]) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>ticker</th>\n",
       "      <th>trial_id</th>\n",
       "      <th>lead_sponsor_name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>phase_category</th>\n",
       "      <th>success_prediction</th>\n",
       "      <th>economic_effect</th>\n",
       "      <th>duration_prediction</th>\n",
       "      <th>success_composite</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>513354</th>\n",
       "      <td>1999-10-18</td>\n",
       "      <td>WINT</td>\n",
       "      <td>NCT00004500</td>\n",
       "      <td>Windtree Therapeutics</td>\n",
       "      <td>A Multicenter, Randomized, Controlled Trial Co...</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.060</td>\n",
       "      <td>0.490</td>\n",
       "      <td>1841.000</td>\n",
       "      <td>0.279</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>512527</th>\n",
       "      <td>1999-10-18</td>\n",
       "      <td>UTHR</td>\n",
       "      <td>NCT00004497</td>\n",
       "      <td>United Therapeutics</td>\n",
       "      <td>None</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.950</td>\n",
       "      <td>0.600</td>\n",
       "      <td>5637.000</td>\n",
       "      <td>0.805</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32118</th>\n",
       "      <td>1999-10-29</td>\n",
       "      <td>NVS</td>\n",
       "      <td>NCT00000174</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>None</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.920</td>\n",
       "      <td>0.490</td>\n",
       "      <td>2065.000</td>\n",
       "      <td>0.770</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36726</th>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>PFE</td>\n",
       "      <td>NCT00003343</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>A Randomized, Double-Blind, Placebo-Controlled...</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.300</td>\n",
       "      <td>0.170</td>\n",
       "      <td>4664.000</td>\n",
       "      <td>0.290</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36723</th>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>PFE</td>\n",
       "      <td>NCT00003720</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>A Multicenter, Dose Escalating Study In Patien...</td>\n",
       "      <td>phase_1</td>\n",
       "      <td>0.910</td>\n",
       "      <td>0.600</td>\n",
       "      <td>4679.000</td>\n",
       "      <td>0.742</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20808</th>\n",
       "      <td>2024-10-25</td>\n",
       "      <td>GSK</td>\n",
       "      <td>NCT06663436</td>\n",
       "      <td>Glaxosmithkline</td>\n",
       "      <td>A Phase 2 Single-Blind, Randomized, Controlled...</td>\n",
       "      <td>phase_2</td>\n",
       "      <td>0.840</td>\n",
       "      <td>0.430</td>\n",
       "      <td>327.000</td>\n",
       "      <td>0.704</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32829</th>\n",
       "      <td>2024-10-27</td>\n",
       "      <td>NVS</td>\n",
       "      <td>NCT06662812</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Disease Characteristics And Treatment Patterns...</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>0.270</td>\n",
       "      <td>0.070</td>\n",
       "      <td>730.000</td>\n",
       "      <td>0.204</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32830</th>\n",
       "      <td>2024-10-27</td>\n",
       "      <td>NVS</td>\n",
       "      <td>NCT06662825</td>\n",
       "      <td>Novartis</td>\n",
       "      <td>Seg-2022-01 Patient Characteristics And Treatm...</td>\n",
       "      <td>not_specified</td>\n",
       "      <td>0.310</td>\n",
       "      <td>0.070</td>\n",
       "      <td>323.000</td>\n",
       "      <td>0.233</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>511796</th>\n",
       "      <td>2024-10-28</td>\n",
       "      <td>TEVA</td>\n",
       "      <td>NCT06664619</td>\n",
       "      <td>Teva Branded Pharmaceutical Products R&amp;D, Inc.</td>\n",
       "      <td>A 4-Week, Double-Blind, Placebo-Controlled, Pa...</td>\n",
       "      <td>phase_3</td>\n",
       "      <td>0.850</td>\n",
       "      <td>0.440</td>\n",
       "      <td>560.000</td>\n",
       "      <td>0.727</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>513423</th>\n",
       "      <td>2024-10-28</td>\n",
       "      <td>XBIT</td>\n",
       "      <td>NCT06664502</td>\n",
       "      <td>Eyebiotech Ltd.</td>\n",
       "      <td>A Phase 1/2A 2-Part Study Consisting Of An Ope...</td>\n",
       "      <td>phase_2</td>\n",
       "      <td>0.870</td>\n",
       "      <td>0.470</td>\n",
       "      <td>550.000</td>\n",
       "      <td>0.731</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>48998 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             date ticker     trial_id  \\\n",
       "513354 1999-10-18   WINT  NCT00004500   \n",
       "512527 1999-10-18   UTHR  NCT00004497   \n",
       "32118  1999-10-29    NVS  NCT00000174   \n",
       "36726  1999-11-01    PFE  NCT00003343   \n",
       "36723  1999-11-01    PFE  NCT00003720   \n",
       "...           ...    ...          ...   \n",
       "20808  2024-10-25    GSK  NCT06663436   \n",
       "32829  2024-10-27    NVS  NCT06662812   \n",
       "32830  2024-10-27    NVS  NCT06662825   \n",
       "511796 2024-10-28   TEVA  NCT06664619   \n",
       "513423 2024-10-28   XBIT  NCT06664502   \n",
       "\n",
       "                                     lead_sponsor_name  \\\n",
       "513354                           Windtree Therapeutics   \n",
       "512527                             United Therapeutics   \n",
       "32118                                         Novartis   \n",
       "36726                                           Pfizer   \n",
       "36723                                           Pfizer   \n",
       "...                                                ...   \n",
       "20808                                  Glaxosmithkline   \n",
       "32829                                         Novartis   \n",
       "32830                                         Novartis   \n",
       "511796  Teva Branded Pharmaceutical Products R&D, Inc.   \n",
       "513423                                 Eyebiotech Ltd.   \n",
       "\n",
       "                                           official_title phase_category  \\\n",
       "513354  A Multicenter, Randomized, Controlled Trial Co...        phase_3   \n",
       "512527                                               None        phase_3   \n",
       "32118                                                None        phase_3   \n",
       "36726   A Randomized, Double-Blind, Placebo-Controlled...        phase_3   \n",
       "36723   A Multicenter, Dose Escalating Study In Patien...        phase_1   \n",
       "...                                                   ...            ...   \n",
       "20808   A Phase 2 Single-Blind, Randomized, Controlled...        phase_2   \n",
       "32829   Disease Characteristics And Treatment Patterns...  not_specified   \n",
       "32830   Seg-2022-01 Patient Characteristics And Treatm...  not_specified   \n",
       "511796  A 4-Week, Double-Blind, Placebo-Controlled, Pa...        phase_3   \n",
       "513423  A Phase 1/2A 2-Part Study Consisting Of An Ope...        phase_2   \n",
       "\n",
       "        success_prediction  economic_effect  duration_prediction  \\\n",
       "513354               0.060            0.490             1841.000   \n",
       "512527               0.950            0.600             5637.000   \n",
       "32118                0.920            0.490             2065.000   \n",
       "36726                0.300            0.170             4664.000   \n",
       "36723                0.910            0.600             4679.000   \n",
       "...                    ...              ...                  ...   \n",
       "20808                0.840            0.430              327.000   \n",
       "32829                0.270            0.070              730.000   \n",
       "32830                0.310            0.070              323.000   \n",
       "511796               0.850            0.440              560.000   \n",
       "513423               0.870            0.470              550.000   \n",
       "\n",
       "        success_composite  \n",
       "513354              0.279  \n",
       "512527              0.805  \n",
       "32118               0.770  \n",
       "36726               0.290  \n",
       "36723               0.742  \n",
       "...                   ...  \n",
       "20808               0.704  \n",
       "32829               0.204  \n",
       "32830               0.233  \n",
       "511796              0.727  \n",
       "513423              0.731  \n",
       "\n",
       "[48998 rows x 10 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_clinical.sort_values(\"date\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#https://clinicaltrials.gov/study/NCT06628310"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.10"
  },
  "vscode": {
   "interpreter": {
    "hash": "b7bc88ef2312de8ccb6fe32ee45ed1b303064bae6342b11333199520ddc77aae"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
